<< View other programs for patients and families.
2026 Seminar for Patients - Recordings and Transcripts
When is treatment needed for HCL and HCL variant (HCLv)? What are my options? What can I expect during recovery? Explore the sessions from our 2026 seminar for answers to these questions, practical nutrition tips, and an introduction to the HCL Patient Data Registry. Watch the recordings at your own pace, read the transcripts, or browse the audience Q&A.
How to Explore Each Session
Meet the speaker: Click the down arrow (⌄) next to the speaker’s name to read their biography.
Explore key takeaways: Read the introduction and highlights for a quick overview of the presentation.
Watch or read: Choose how you prefer to explore the session — watch the video (▶) or click the down arrow (⌄) below it to read the full transcript.
Explore the Q&A: Click the down arrow (⌄) next to the Q&A section to read questions and answers.
Listen to the expert panel: Click the play button (▶) on any audio recording to hear the doctors share their perspectives.
Video captions: The video format provides AI-generated captions that occasionally contain errors. For the most accurate text, view the transcript below each presentation. Each transcript has been reviewed by HCLF staff to ensure it reflects the presenter’s remarks accurately.
Note: The 2026 patient seminar was a hybrid meeting, with speakers and some patients and families participating in person, and many more individuals participating online. The recordings are of a live, in-person event, and listeners might detect minor microphone interference or background noise.
Deepening Your Knowledge of HCL and HCLv
Whether you're newly diagnosed, preparing for treatment, or looking to better understand your options, these expert-led sessions offer clear, practical information about HCL and HCLv. Learn about the disease, explore treatment approaches, and hear how specialists make care decisions based on each person's needs and circumstances.
Understanding Hairy Cell Leukemia
Dr. Kerry Rogers, The Ohio State University
-
Dr. Rogers is a hematologist-oncologist and an associate professor at The Ohio State University Comprehensive Cancer Center. She specializes in caring for patients with hairy cell leukemia, chronic lymphocytic leukemia, and other blood disorders. Her research focuses on developing safer, more effective treatment strategies, including targeted and chemotherapy-free approaches.
Dr. Kerry Rogers explains the basics of HCL, including how it is diagnosed, when treatment may be needed, and why some people can be monitored without treatment. She also explains remission, relapse, and measurable residual disease (MRD) in terms that help people living with HCL and their families better understand conversations about their care.
Key Takeaways:
HCL is rare, but the outlook is often reassuring.
Treatment is not always needed right away.
Blood counts and symptoms help guide treatment decisions.
Remission can be complete or partial, meaning that the signs of HCL have disappeared or decreased after treatment.
Relapse does not automatically mean immediate treatment.
MRD testing looks for very small amounts of remaining leukemia.
View a recording of Dr. Rogers’ presentation below.
-
HCL 101: Understanding Hairy Cell Leukemia
HCLF Patient Seminar 2026 | Speaker: Dr. Kerry Rogers, The Ohio State University
Overview
A brief overview of what I'm going to be talking about for this segment. I have a little bit of information on hairy cell leukemia, how it's diagnosed, and who's living with it. I'm then gonna go through treatment indications or why someone might need treatment for hairy cell leukemia. And then, I have definitions of response, so the response categories that physicians and researchers use.
And then the definition of something called measurable residual disease, which I think everyone's probably hearing about a lot these days if you follow any of the research.
Hairy Cell Leukemia
So hairy cell leukemia is a rare chronic B-cell leukemia. So this is a type of blood cancer. The cells that become cancer cells are white blood cells called B lymphocytes. So these are immune system cells. So we classify this as a blood cancer, but you can also think of it as a cancer of immune system cells.
So that sometimes helps people understand some of the things that happen or that they experience with hairy cell leukemia. So I think it's important to mention that. And leukemia is a kind of cancer of white blood cells, but those are immune system cells. This was described in the late '50s, by two different groups as leukemic reticuloendotheliosis. And that's a picture of Bertha Bouroncle, who was at Ohio State. And she really did a lot of the work that led to us all being here today, understanding this disease better and making sure we have good progress.
If you don't define something you definitely can't help diagnose and treat it better.
Facts About Hairy Cell Leukemia
So here's a few facts about hairy cell leukemia. This is a rare leukemia. So this is approximately two percent of adult leukemias, and leukemias are actually a rarer adult cancer. So the really common ones are things like breast cancer, lung cancer, and prostate cancer in men. So leukemias are rare in general. And this is about eleven hundred new cases in the US. I have the US data because they follow it through something called SEER. Just for comparison, I was telling someone earlier at the breakfast, chronic lymphocytic leukemia, which is the most incident of that leukemia, so the one that's diagnosed the most frequently, is about twenty-three thousand cases a year, and this is about one thousand cases.
So that kind of gives you an idea of how rare this is. The other way to think about it is that if you put a hundred thousand people in a room and follow them for a whole year, you're gonna have less than one case of hairy cell leukemia. You're gonna have point three cases. Obviously, you can't have a point three case, but like you won't even have one case. And then the demographics of people experiencing hairy cell leukemia, the median age of diagnosis is fifty-five.
This is not a disease of children, but it does actually have a pretty big age spread. So you do see people in their 20s, definitely 30s and 40s, and then you do see older people diagnosed with this. And if you look at the distribution of ages of diagnosis, in some of those graphs you see actually a lump of people diagnosed in their 30s, 40s, and then a later lump too. So even though the median is 55, it's actually a big spread for kind of the age range of people at the time of diagnosis.
This is more common in men and more common in white individuals, and that's probably having to do with the genetic risk factors for hairy cell leukemia. So it's certainly not exclusively in white people but that is more common. And that's actually true for the non-Hodgkin's lymphomas too. If you look at Asian populations, more T-cell lymphomas and, white populations more B-cell ones. Just something to think about with the genetics of it. And then I really wanna highlight that the expected survival for people living with hairy cell leukemia is decades.
So most people get to have a normal lifespan. It is not curable, so they will be living with this over their lifespan. But it is not something that significantly shortens people's lives. And I think that's really important to realize when you're thinking about how we treat hairy cell leukemia and how to think about it. That's not true of all leukemias, but it's true for the most part in hairy cell leukemia. So it is possible to die of hairy cell leukemia, but that is not common.
Also, nobody lives forever, so if you look at survival statistics, at some point people die of other things. So you'll never have a study where everyone lives forever if you follow them for decades. So don't worry if you see an average survival of fifteen years thinking that someone in their twenties is only gonna live fifteen years. If you think about it people in their eighties probably aren't expecting to live more than fifteen years. You just have to think about those sorts of things.
And if you see some data on survival in hairy cell leukemia, realize that most people are enjoying their normal lifespan.
Diagnosis of Hairy Cell Leukemia (HCL)
The diagnosis of hairy cell leukemia requires verifying the presence of the leukemia cells. So to have hairy cell leukemia, you have to have hairy cell leukemia cells. For hairy cell leukemia particularly, this usually requires a bone marrow biopsy. That is where the hairy cells like to live. They also like to live in the spleen, but we don't really do spleen biopsies.
They are in other places. So they are in the blood, 'cause they're blood cells, the bone marrow. They're in the lymph nodes, definitely the spleen. They can be elsewhere in the body. So this is a blood cancer. It can go anywhere in the body that blood cells go. In some cases, it even forms areas in the bone where… not the bone marrow inside the bone, but the outside of the bone. And that's okay. So just because it is multiple places in the body does not make it less treatable.
The leukemia is defined by three different categories. So this is how doctors first learned to categorize leukemias. So way back in the day when we had microscopes, and that was it, was classified by appearance. So pathologists, physicians, researchers would look through the microscope and say, "Okay, that's what it looks like. That's how we're gonna classify it." As time went on, we used something called immunophenotype, which is… You can think of it as like the markers on the cell or sometimes inside the cell. So then, pathologists mostly are the doctors that do this would say "Okay, these cells look the same, but they have totally different markers on them."
So then you can tell this one's hairy cell leukemia and this one's splenic marginal zone lymphoma. And then the more recent thing we use to classify, and this isn't just hairy cell, this is all like kind of blood cancers and other things and this applies to classifying like subtypes of breast cancer too. But the other thing that then people have used most recently is mutations. So these are alterations in the DNA. They're not alterations in genes that you share with family members.
They're just the genes in the leukemia that is part of how the cell broke and became a leukemia cell. And in classic hairy cell leukemia, most of the hairy cells will have a mutation in a gene called BRAF, and the mutation is the V600E mutation. So if you see that in a cell that looks like hairy cell leukemia with the right markers, you can be very confident that this is classic hairy cell leukemia. So there's a variant form, which is HCL-v.
This one has slightly different markers. It actually looks like hairy cell, so the morphology is very similar. So you look at them and say, "These things look the same." But then when you look at the markers, you're like, "Okay, the markers are a little different." And then the mutations in it are actually different. They usually have MAP2K1 mutations and not BRAF mutations, so you can start to classify these things out. the WHO has recently grouped HCL-v in with a group of these more slow-growing leukemias lymphomas and called it splenic B-cell lymphoma with prominent nucleoli.
That is a description of what it looks like, and it includes some other entities like B-PLL. That wasn't an overly popular decision among us doing research in hairy cell leukemia. And I think we still, when we see people in the clinic, use that research done in hairy cell leukemia variants and define it that way ourselves to help take care of patients. And my colleague, Chris Oakes had an update on this at the scientific meeting but I think there's high interest in kind of sub-classifying things beyond just this new category here.
So if someone has questions about that, we can discuss it later now the really fun part of the talk where there's pictures.
Morphology or Appearance of Hairy Cell Leukemia
This is the morphology or appearance of hairy cell leukemia. So they appear like mature lymphocytes. And if you don't know what a mature lymphocyte is, that's okay, don't worry about it. But the hairy cells are these two big purple ones here in the middle. These kind of lighter pink ones are actually red blood cells. You can see they're kinda disc shaped. I think most people have at least seen a Red Cross poster with a red blood cell on it.
And then these little tiny purple dots, see there's three of them here, those are actually blood platelets. But these big purple blobs, those are actually the leukemia cells in the blood. This is a picture of hairy cell leukemia variant, and I took this picture from the ASH Image Bank. That's a professional society for hematology that has actually a bank of neat pictures that you can use. This image doesn't have the villus-like cytoplasmic projections or hairs. My next slide does. But I wanted to get this picture 'cause you can see the nucleus, which is the darker purple splotch in the middle, and then, see there's that kind of light spot in it that looks like an egg yolk.
So that's It mostly looks like a kidney bean shaped nucleus, and then that nucleolus makes it look like a fried egg. It's like, back when they were only classifying things by the way they looked, you had to come up with some cool way to describe it. Here are some nice photos of hairy cell leukemia in the blood.
Hairy Cell Leukemia in the Blood and Bone Marrow
The red blood cells here, you can see they kinda are stuck together and look like seaweed. That's just the part of the blood film that this is. Don't worry about that. The arrows are pointing to hairy cells, and see how they look blurry or fuzzy at the border? See how this kinda looks a little blurry or fuzzy? Those are the hairs. So that's what the little hairs look like on hairy cell leukemia and then this is a picture of the bone marrow just while we're showing cool pictures.
So these kind of pink blobs in here, that is actually bone. So there is some amount of bone structure in the inside of the bone marrow. So this is not like the outside of the bone. My roommate from med school is an orthopedic surgeon, so like the outside of the bone, that's her part of the bone. And like the marrow, that's like the hematology part of the bone.
But you still have some of the bone, like inside the marrow. These things that look empty here are actually fat globules. So your marrow actually has a lot of fat in it, which is cool. And then all this stuff in here is actually the blood cells, this pink stuff. This is a special stain, and you can see the difference between this picture and this one is that this one has all these kind of black, see the little black kind of daisy stuff in there.
That's a special stain that looks for something called reticulin, which is like a fibrous. You can think of it like fibrous is tough tissue, like scar tissue type stuff. And the hairy cells somehow send a signal to the bone marrow to make a bunch of fibrous there, and that helps decrease the amount of healthy cells in the marrow, which is one reason in some cases that blood counts are low in hairy cell leukemia because the marrow gets this fibrous in it, and then the healthy blood cells can't do their job.
Do you ever have a garden that just gets dirt or something, like hard packed on it and nothing can grow? That's kind of the idea. Treatment clears that out and can resolve that so that the healthy marrow can regrow. But that's what it looks like. This is from my colleague, Dr. Lozanski at Ohio State.
Immunophenotype and Molecular Testing
Okay, so that's what it looks like. Now here's the less exciting part with no pictures. There's an immunophenotype. So this is what the markers are on the cells, and this can be determined a couple different ways but these are clonal B-cells. So healthy normal B-cells are all a little bit different from each other because they're immune system cells that have to go after everything there is you wanna fight off different bacteria and viruses. But these are abnormal B cells that are all like clones of each other or copies of each other because they're all like the, the cancer cells.
And they all have these markers, so things like CD19, CD20, which are B -cell markers, CD11c. So these are like just what we see on the cells that help define them when we're trying to diagnose someone with hairy cell leukemia. CD25 is underlined because it's not really present in variant hairy cell. These are a couple markers you'd expect not to see in hairy cell. Everyone's a little different, so sometimes the immunophenotype's a little different, but this is the common immunophenotype. And then the other thing that supports the diagnosis is a BRAF V600E mutation for classic hairy cell leukemia, and there's two different ways that's done.
So this first part, immunophenotype, I'm gonna show you a couple techniques for how we determine that. And then I don't have a lot of ways to show you how we look at the BRAF mutation but there's a couple different ways of sequencing, to sequence it. One is just to sequence the DNA. So that can be done with something called Sanger sequencing, which is like the really old school sequencing that was coming out when I went to college, and then NGS is the next -generation sequencing platform.
I would like to say I fully understand how it works, but I do not. And then interestingly, the BRAF V600E mutation, there's actually an immunohistochemistry stain or a stain that picks up mutant BRAF but non-mu… not non-mutant BRAF. So you can actually take a bone marrow, put a special stain on it, and it will only… the stain will only stick to the bone marrow if the BRAF V600E mutation is there. So there's actually a special way that you can test for that mutation which is critical because a lot of times in hairy cell leukemia there's not that many cells circulating in blood or when you do a bone marrow biopsy you can't get the aspirate or the liquid part of the bone marrow.
It doesn't suck out well. You just can't get a sample probably because of the fibrosis. And so you can actually take the bone marrow and look for this mutation with antibodies, which is this immunohistochemistry which is really important.
Immunophenotype Testing Methods
These are just two ways to determine an immunophenotype. I tried to simplify this with BioRender. I'm not sure that really worked, so hopefully it at least looks okay. So flow cytometry is a special technique where you need a single cell suspension. So you can take either a bone marrow aspirate, which is the liquid part of the bone marrow you can take a blood sample, or, if it's a lymph node, you have to break it up into a single cell suspension.
Then you paint it with antibodies that bind to these different markers you're looking for, and then you fire it in front of a laser because the antibodies have a little fluorescent thing on it. And then you get these neat little plots out at the end that show you which cells have what markers in combination with each other. One of the postdocs in the lab next to the research lab I work in described this to an undergrad as "Antibodies and lasers." And then they did it, and the undergrad's "Cool, so like you put the tube in and dots appear?" It's underwhelming when you think of it that way.
But that helps you know what marker's on it, 'cause you can see which fluorescent things are in which cells. Immunohistochemistry is a very different technique, so this requires a sample embedded in paraffin. So that can be a bone marrow core biopsy, which is like kind of the, the solid sample they take, not the liquid sample in a syringe. It can be from lymph nodes. It can be from like a, an actual like bone lesion, not bone marrow lesion. Spleen biopsies, this is what you do.
They embed it in paraffin, they slice it, and then they paint it with antibodies against things. You can use the BRAF V600E antibody, or you can look for things like CD20, PAX5, so different things to help identify this hairy cell. And then it's looked at under a microscope, not dots and lasers.
When to Treat Hairy Cell Leukemia
But when to treat hairy cell leukemia is now a different topic. No more lasers and pictures. But treatment is only really needed when there's something to improve. So I have patients who have had hairy cell for five or more years and have not needed treatment for it, and they feel well, and they go about their lives, and their blood counts are okay, and it's fine. In some other chronic B-cell leukemias, they do have randomized studies showing that observation doesn't… or observing people without treatment or treating early, it doesn't make a difference for survival.
Meaning early treatment doesn't help people live longer or better. That has not been done in hairy cell leukemia probably because it's so rare. But we all have patients that have never needed treatment that are living happy, healthy, and productive lives. So I see no reason why that should be different for hairy cell leukemia. Many people have a period of observation before treatment, which includes, of course, visits with your doctor, monitoring blood counts, thinking about symptoms. Sometimes this is called watchful waiting.
I like to call it observation. I think that sounds better. I don't know why but that's what it is. And again, people can go years without needing treatment. And even after treatment, if the hairy cell comes back, there can still be a period of more observation before treatment's needed again. So just because there's signs the hairy cell might have returned doesn't mean you have to do treatment the next day; and that can be years, by the way.
Low Blood Counts that Need Treatment
So low blood counts that need treatment are usually when you start to see that blood counts are getting low enough. Lots of the chemotherapies we use for Hairy Cell, cladribine or pentostatin, will lower the blood counts further, particularly cladribine which is given over a short period of time. So you wanna start when you still have okay blood counts if you get the opportunity to, so that when it drops with chemotherapy you don't end up in worse trouble with them.
And so those are the cutoffs for when doctors start thinking about treatment. So it's a neutrophil count less than 1,000, which is usually reported as one on lab slips. The units make it 1,000. Hemoglobin less than 10 grams per deciliter is the United States designation. And then I think that's 100 in Canada, is 10. Am I looking for a chart? Yeah. And then platelet count less than 100. That's 100,000, but it looks like 100 on the slips. And some people can have the 90s for years, and that's totally fine.
But if you see it's 150, 110, 90, like going down, really gotta think about treatment. And then some people don't know they have hairy cell leukemia until their blood counts are severely low. So if your blood counts are already well below these marks or you're needing transfusions when you're diagnosed, then treatment should be done right away. Not within like hours, you've still got some time to figure it out, but fairly quickly.
Findings and Symptoms Requiring Treatment
And then I bet some people in this room know more about this than I do. But hairy cell leukemia can cause symptoms. The way I like to explain this is it's cancers of immune system cells, so they can release some of the same hormones that get released during infections. Except there's no infection, they're just abnormal immune system cells, and they do this. So that can cause fatigue, drenching night sweats. And I mean sweats so that you and everyone in bed with you is wet, including your spouse and your dog.
Unexplained weight loss. Everyone always says, "Oh, I wish." You really don't when it happens. Also this GLP-1 receptor agonist has been clinic for a while. You walk in and someone's lost like 30 pounds. They're like, "I had Ozempic." And you're like, "Oh, thank God." Yeah. But it's probably 20% of your body weight or problematic if you're thin to begin with. And then many people describe living with fatigue. I absolutely cannot improve mild chronic fatigue. This has to be fatigue that's impacting your ability to do what you need or want to do regularly.
If you're just a little tired, I would love to say I can fix that, doctors stopped giving out dexamethasone in like the '60s for a reason. So I definitely can't fix that. But if there's fatigue that's really impacting your life this could be why. I do think making sure that like your vitamin D level is checked and you don't have sleep apnea, 'cause like treating hairy cell leukemia doesn't fix sleep apnea. So you gotta make sure those things are crossed off the list. And then if you have hairy cells causing problems, so it can cause low blood counts by filling up the bone marrow, but it can also cause lymph nodes that are a problem, bone lesions that can hurt.
If your spleen's like a little big, that's cool. You have plenty of space in the abdomen. But if your spleen's filling up like your whole abdomen, best to do something. I had a patient that didn't know he had hairy cell and was trying to do sit-ups to get his abs back, and it was like all spleen. So just, that's problematic.
Definitions of Response and Remission
And then just briefly, these are some definitions of response and remission. So the table has the formal definition, which is what physicians and researchers use when we do clinical trials or studies to understand the outcomes of treatments. But most people, if you're not getting treated in a clinical trial, your doctor will just say you're in remission, and that means things are better. There's less hairy cell. You're feeling better. Your blood counts are better. And you don't have to worry about if it's a complete or a partial remission.
So if someone says, "Hey, you're in remission," or you've had a nice response, that's okay. You don't have to worry about what type. But as you can see in the table, these are types we use when we do research to categorize it better. So you might hear about some of these today. Complete remission means the blood counts are recovered. You don't have an enlarged spleen anymore, and there's no hairy cells visible in the bone marrow.
Partial is like a fifty percent reduction; the blood counts are recovered”, but there's still some hairy cells.
Relapsed and Refractory Disease
Progressive disease is obviously things getting worse from hairy cell, and then no response is in the middle. Relapse is a sign of return of hairy cells to the body. So this could be blood counts getting lower, hairy cells appearing in the blood, the monocyte count dropping. It doesn't always need treatment. Early relapse, most physicians and researchers say early relapse would be within two years of doing your treatment. And refractory disease usually refers to leukemia that had no response or a very transient response to treatment. So that would be getting a drug like venetoclax, not seeing any change in blood count symptoms, spleen size, or seeing that improve for four weeks and then get worse while you're taking the drug.
That is not a common experience in Hairy Cell Leukemia.
Measurable Residual Disease (MRD)
Okay, and then the last thing I wanna cover is something called MRD, which is very popular right now. And I think the reason this is so popular is, as I said at the beginning, people live a very long time with Hairy Cell Leukemia. And so it's really hard to tell if a treatment is keeping people in remission longer because people are in remission for seven or eight years. I'd be retired by the time we find out if I were to do a study today.
But MRD is basically tests to look for any detectable leukemia cells. So it usually means a deeper remission, and we think that this would mean a longer remission. So it's a way to tell that if someone's a complete or even a partial remission with… it would have to be complete in hairy cell. There's no detectable hairy cells. Then you'd say, "Hey, these people are probably gonna experience a longer time until their hairy cell comes back. We don't have to wait ten years to find out if that's gonna be true." So it's a way to look at a deeper remission, but this is not part of the response criteria on the table on the other page.
So it's it can be tested for in a few different ways in hairy cell flow cytometry, bone marrow immunohistochemistry. You can stain for BRAF mutation. There's a digital droplet PCR that's used for BRAF, and then there's an NGS assay called clonoSEQ. If anyone's curious about these types, you can ask me after, and I'm happy to discuss them in detail.
This transcript has been edited for clarity.
-
HCL 101: Understanding Hairy Cell Leukemia
Questions and Answers with Dr. Kerry Rogers
Is a repeat bone marrow biopsy common after treatment, or can blood counts show the response?
Dr. Rogers: That is a great question. Let me go back to the table. So to calculate a response here using the criteria in this table, you have to get a bone marrow biopsy. Sometimes, especially with cladribine, that's even six months after you get the treatment, because the response continues to improve up to six months.
But you actually need a bone marrow biopsy for this because you need to make sure there are no hairy cells in the marrow or they've improved by X amount. If you are not in a research study or don't need your response categorized like this, it is okay to say, “My blood counts have cleared up.” It's like a clinical remission.
I personally think bone marrow biopsies can be very helpful because the presence of detectable hairy cells in the bone marrow after treatment predicts a shorter time until the hairy cells come back and you have to do treatment again, and it might be a good way just to understand how you're starting out the remission.
For example, whether there are any hairy cells there or not. So I really encourage people to get a bone marrow biopsy, especially if it's going to be about six months after treatment. For pentostatin, it's usually right in the middle of it to see how things are to determine the duration of pentostatin. But I think it's really important that people get bone marrow biopsies, but it's not required for just saying “clinical remission”.
It's only required for the formal response category. And of course, like some people don't want another bone marrow biopsy. Some people had a terrible experience with it. Certainly, I respect that maybe getting a bone marrow biopsy again is not for everybody.
Dr. Banerjil: There are also maybe some global differences on that recommendation as well, access to the testing and resource limitations and also the patient perspective, as Kerry mentioned.
I think typically in Canada, it is probably not standard outside of a clinical trial or a study to get a repeat marrow after completion of therapy unless your counts don't resolve. And then I think you have a good conversation with the patient as to why you would like to investigate further.
And sometimes it's just not enough time, but also there could be elements outside of the response that could be responsible for those changes. So I think there's variability globally around that outside of clinical trials, where if you really do want to document those standards, it's essential.
Dr. Rogers: That's a good point. Sometimes you need to do it after treatment to learn something about why your blood counts might still be low. And I definitely have patients that want to know, and patients that are like, "I do not want a bone marrow biopsy unless I need to learn something new." And I think both are very valid.
What are bone lesions, and what might someone with HCL expect if they have one?
Dr. Rogers: If you think about the bone—maybe your arm bone—there's an outside cortex, which is the hard part that gives the bone its structure. That's like the ortho part of the bone, right? Then inside is the marrow.
So when you do bone marrow biopsies, you're looking at the marrow cavity where the blood cells are produced. A certain number of people with hairy cell leukemia—I've seen a couple of variations on how many; it's less than 10%, for sure—have actual lesions where it's not like actually hairy cells in the marrow cavity where you'd expect to see them, but actually in the cortex or the hard part of the bone.
And this occurs in other blood cancers too, like multiple myeloma very commonly or diffuse large B-cell lymphoma in some cases. The chemotherapies or drug treatments or targeted drug treatments that treat hairy cell leukemia do kill those cells, and then the bone heals. So if someone has a bone lesion from hairy cell leukemia, it gets treated with the same systemic therapy as they're getting to treat the hairy cell elsewhere in their body.
They can cause pain. Usually, in most cases, hairy cell doesn't cause pain in the marrow cavity because that's where blood cells live. But I've had a few patients that have things like arm pain from this, and then that gets better after treatment, and that goes away. I have not seen a fracture or breakage in the hard part of the bone from hairy cell.
I see that in some other blood cancers. And the most common way to look for that is actually a PET scan, which is a scan that uses a radiolabeled glucose to look for cells that are active throughout the body. We don't do that in everybody, but if someone has bone pain, that's how it's diagnosed.
So it's something that sounds scary, but it is something that's very treatable.
Can HCL cause atrophy or a reduction in healthy blood-producing cells in the bone marrow?
Dr. Rogers: In the marrow cavity in a lot of blood cancers, including some cases of hairy cell, you get so many of the leukemia cells in the marrow that it crowds out the healthy cells, and then you can't make blood cells well.
So it's like having too many weeds in your garden, and then the vegetables don't grow. But in some cases in hairy cell, it actually causes fibrosis or you'll see like aplasia, which is like the fancy word for atrophy in the bone marrow, where something that's released by even just a few hairy cells causes the healthy blood cells to just quit.
And so you just don't see healthy blood cells there, and it's got to be some hormone or factor released by the hairy cells that causes this. So you do a bone marrow biopsy and you're like, "Hey, this is empty." There might be a couple of hairy cells, but there's like nothing there. So that's like the garden being hard-packed dirt, so nothing's growing.
In both cases, treatment of the hairy cell will eliminate that and allow the healthy blood cells to grow in. It just takes a few weeks or months for the healthy blood cells to build back up. If you weed your garden, it takes a few weeks for the things to come back, right? So hopefully that answers the question.
Why did the World Health Organization (WHO) use “lymphoma” rather than “leukemia” in its new classification?
Dr. Rogers: That's an excellent question. I don't have a good answer as to why they chose to do that. It's an international panel of, I think, mostly pathologists and researchers. I think what they were thinking is that some of these like slow-growing B-cell cancers were close to each other and weren't categorized right, so they just lumped them together to try to get people to sort it out more, and we are actively doing that.
But it is a selected international panel, and no one asked me. Nor am I qualified for that, like I don't do pathology. The difference between leukemia and lymphoma is where the cells are found. So if it's in the blood, we call it leukemia. If it's in the lymph nodes or tissues, we call it lymphoma.
But many things that get called leukemia are also in the lymph nodes, and things that get called lymphoma are circulating in the blood. So the distinction between leukemia and lymphoma goes way back to the day where we just say, "What does this look like, and where is it?" And then, as we learn what things are, sometimes these categories blend.
So chronic lymphocytic leukemia, the most prevalent adult leukemia, actually has a lymphoma version called small lymphocytic lymphoma, and it's the same cancer, same responses, same biology. It's just if there's less of it in the blood, you confuse everybody by calling it lymphoma. So there are a bunch of slow-growing B-cell cancers that are similar to each other.
I think whether it's called leukemia or lymphoma is like where it's first described. So people are calling these like the splenic lymphomas, so they just lumped hairy cell in the splenic lymphomas. And I think the distinction between leukemia and lymphoma, at least to physicians, isn't a big one because we find the cells in both places.
When diagnosing HCL, do cell appearance, cell markers, or mutations carry more weight? For example, what if a marker such as CD123 is absent?
Dr. Rogers: So again, I'm not a pathologist, and if my colleague Dr. Lozanski was here, he'd probably give you a better answer. But I will say all that information goes in the pot.
It helps to decide what it is. If you have an immunophenotype that's close but not exactly classic hairy cell leukemia, and you have a BRAF mutation, they're going to call that classic hairy cell leukemia. If you have a perfect immunophenotype for classic hairy cells but don't have the BRAF mutation in the cells, you might still call that classic hairy cell leukemia.
But the pathologists actually have a whole conference to discuss how to best classify these, because nature does what it's going to, and all of this is just our attempts to categorize it so we can understand it. But the mutation can be more important than immunophenotype.
Does the percentage of cellularity in a bone marrow sample affect the diagnosis or treatment?
Dr. Rogers: It does not for diagnosis. So if any of the cells are there that they can find that are hairy cell, what percent of the marrow it is doesn't matter. But it can matter for treatment, and mostly it matters what percent of the cells are there, and then what percent of the cells in the marrow are healthy.
But it could be that there's ninety percent hairy cell and five percent healthy cells. Could be that there's five percent hairy cells, five percent healthy cells and a bunch of fibrosis. So it gets a little complicated.
How does HCL affect life expectancy?
Dr. Rogers: So impact on life expectancy is sometimes really hard to determine because you have to have a group of people that are otherwise as healthy, of the same sex and age, in the same country and environment, and look at how long they're living.
And so you have to match people with hairy cell leukemia to healthy controls to assess life expectancy. Most of the time you look at like the average life expectancy for a general population of people at the same age and gender. But things like socioeconomic status can also affect life expectancy. Most of the recent studies in hairy cell leukemia since the kind of development of purine analog treatment show that people have similar or kind of overlapping lifespans.
There's one suggestion or study suggesting people diagnosed younger than 40 years old might have a life expectancy that was maybe a few years shorter than it would be without hairy cell leukemia. So you could have some decrease in lifespan. But again, you're still talking about decades at that point.
But it would be like, maybe a few years less than you would live otherwise. And when you look at the statistics of how that's done, that might be people that died at the time of diagnosis or shortly after from things like infection, then that decreases the lifespan for the whole group there.
Dr.Bhat: I completely agree with what Kerry said. To put that in perspective, we had only interferon and splenectomy as treatments for hairy cell leukemia before we had cladribine and other purine analogs.
The average life expectancy was around three to four—four to five years. And when we had these highly effective treatments, now, with long-term follow-up, that's when we saw that the life expectancy was matched to a normal population. So treatment did make a big difference there. And I think, just to add to the point that Kerry mentioned about infections, our supportive care and our understanding of how to treat in the setting of acute infections has also probably improved the outcomes for patients overall, increasing that life expectancy compared to what we did before.
And I'll go into some of that in my talk.
Dr. Rogers: One thing I like to tell my patients is, “I expect you to be around for decades with this, unless you're in your mid-90s—then probably not.” So you need to make sure that you stay healthy, otherwise people die of heart attacks and things, right?
So get your lipids checked. You know what I'm saying? Exercise and eat like you're going to be here a while. And sometimes people find out they have leukemia and rightfully think they're dying, and they quit managing their diabetes. I'm like, "you have to get back on the diabetes management train."
Edited for grammar, spelling, and readability .
Preparing for Treatment and Recovery
Dr. Versha Banerji, CancerCare Manitoba
-
Dr. Banerji is a hematologist, clinician-scientist, and senior scientist at CancerCare Manitoba. She is also an associate professor at the University of Manitoba. Her clinical and research work focuses on blood cancers, including hairy cell leukemia and chronic lymphocytic leukemia, with particular interests in novel therapies, treatment resistance, cancer metabolism, and sex-based differences in blood cancers.
Dr. Versha Banerji offers a practical guide to preparing for HCL treatment and recovering afterward. She explains what to expect during monitoring and treatment, how to reduce infection risks, when to contact your care team, and how to plan for work, travel, and everyday life. The presentation also highlights the importance of preventive care, emotional support, and allowing time for recovery.
Key Takeaways:
Monitoring is an active part of care.
Treatment decisions are personal.
Plan ahead where possible.
Infection prevention is a shared effort.
Fever during treatment needs urgent attention.
Recovery takes time.
Care continues after treatment.
View a recording of Dr. Banerji’s presentation below.
-
Navigating Hairy Cell Leukemia: Your Roadmap for Treatment, Recovery, and Life Beyond
HCLF Patient Seminar 2026 | Speaker: Dr. Versha Banerji
Good morning, everyone. Thank you very much for the kind invitation to speak here today. And today I hope to maybe lay out a bit of a roadmap. Many of you have lived experiences whose experiences are probably more pertinent than this framework that I'm going to provide. But some people may not have gone through their entire journey, so this gives them a little bit of an overview. And I'm from Winnipeg, Manitoba, and I'm a physician and scientist there. And I have a lot of experience treating patients with hairy cell leukemia.
Objectives
The objectives for today are speaking to the patient journey, preparing for treatment, what patients should expect during that treatment, and then recovery and life after. And there's some bullet points there that we'll discuss as we go along. Some of this will also overlap with Dr. Bhat's presentation. But my goal is not to go into the weeds. It's really to give you a general overview.
Hairy Cell Leukemia Is a Highly Treatable, Chronic Condition With a Predictable Path Forward
So now that you know how to be diagnosed with hairy cell leukemia and the criteria for that diagnosis, what happens along that journey? So depending on when you're diagnosed, you may fall into a few categories. One is the watch and wait period, and then the other is the active treatment period. So the watch and wait period involves active surveillance because you have not met criteria for treatment yet. And that is probably a time in which most patients are detected if they're already in the medical system.
But I think in patients who are not in the medical system, they may present a little bit later, and as a result, may require active treatment. But what can we do to make either of those journeys better? So the protection and the recovery phase, depending on where you are, and then adjusting to the new normal. So I'm not sure if this projects very well.
Vaccination Recommendations
One of the things that we've done at our institution is created recommendations to help protect in that watch and wait period. And part of the reason for that is your immunity is best preserved earlier in the time period prior to initiation of therapy. And so these are recommendations that we have for our patients for hairy cell leukemia and some of the other lymphoproliferative disorders such as chronic lymphocytic leukemia. And so we know that patients' immune systems can change over time.
One, because of age, and two, because of the functionality of those immune cells. So we want to capture patients at the best time possible, so the earlier you are in that treatment journey, the better it is. The challenge is, in the health system as a whole, most of these recommendations are made for patients with chronic illnesses or patients over the age of sixty-five. And we've just heard from Dr. Rogers that a lot of our patients are younger, so this is not part of their routine medical care, and therefore it's often overlooked.
And so this is why it's very important that we empower the patients and their primary care providers with the list of things that we would recommend. So we do recommend the flu shot annually and the COVID-19 vaccine. We want people to be vaccinated against routine vaccines that would have been done throughout their younger ages. But we do also recommend the shingles vaccine, the RSV vaccine. And I think it's important to note that a lot of times in North America, hepatitis vaccination was recommended for travel purposes only.
But the reality of the situation is, with the immigration patterns changing, you don't have to travel anywhere to be exposed to hepatitis. So we've now started to make those recommendations because when you get treated with some of the agents, the challenge is if you have hepatitis that is undetectable, then you may actually reactivate hepatitis and become sicker and not be able to receive treatment adequately. And then lastly, we recommend the pneumococcal vaccine. So these are obviously in line with the Canadian recommendations. I have left this open in terms of keeping it broad because there might be different formulations across the globe on the types of vaccinations.
But we want to have patients vaccinated against pneumonia and then ensuring that the patient population over the age of sixty-five is covered.
Age-Appropriate Cancer Screening
So the other thing that we need to think about is this propensity for second cancers. So as Dr. Rogers mentioned, this is a cancer of immune cells, and immune cells are important in protecting your body and your organs against other cancers. So there's… I will say that your immune system is a communication network, and now you have a group of cells that are stubborn and they don't like to communicate properly, and as a result, the teamwork is broken down and the system fails, and you can't clear the bad cells from the tissues within your organ system.
And so this is another challenge because we just told you that people can be diagnosed in their 20s and all the way up to their late 80s, 90s. The challenge is the recommendations for screening actually start at specific ages or with specific risk factors, so we need to empower the patients with the information around how we investigate them. So there are strict age criteria depending on your risk for breast and colon screening. For lung cancer, we have smoking requirements for lung cancer screening, and then if you're sexually active, for Pap smears, and prostate screening differs globally around what those recommendations are.
So in my opinion, you can meet those age requirements, but one of the main things that you need to think about are symptoms. And if you have a symptom as a patient, it is really important that you communicate that to your primary care provider so they can start the appropriate investigations, because you may not fall into those screening categories. And one thing I think we need to do a little bit more education around is skin as a potential area where malignancies arise. So skin checks are really important.
Patients are at risk of both non-melanomatous skin cancers, and this could be independent of receiving treatment and part of their cancer journey. We always have patients protect themselves against the sun to minimize that risk of skin cancer. So I always say, please… everyone says, "Yeah, I wear a hat." I'm like, "Is it a baseball hat?" And they're like, "Yeah." And I'm like, "Yeah, so your ears are completely unprotected," and that's where I see the majority of skin cancers in my patients. So a broad-brimmed hat is really important.
And then sunscreen is important, and UV-protective clothing. So things that people don't make a habit of in their lives overall, and then you're trying to change years of habit over time. Really important to understand that, and it protects not just you, but also your family members if you keep that education stream alive. So age-appropriate cancer screening is also a very key piece of information that I provide patients, whether they're through the treatment journey but mostly in that watch and wait period.
Phase 1: Watch and Wait Is a Strategy of Active Surveillance, Not Inaction
Why do we have this strategy of watch and wait? Dr. Rogers really spoke to the fact that early intervention may not provide benefit. And so what we are really looking for at this point is building the lifestyle that is going to help you get through this journey, but make you in the best health possible when and if you might require treatment. And we talked a lot about the fact that we do not want to treat you for symptoms that might not be related to your current condition, and that's often a conversation I have with patients because fatigue is one of the most common symptoms.
But we need to make sure we get to know each other through this journey, and is the fatigue related to financial stress, family stress? Is it related to medical conditions? And especially if the counts are stable and are not changing and not meeting criteria. So we're always trying to balance the disease burden with the quality-of-life impacts because ultimately my goal in a cancer that is not curable is to ensure that I'm improving your quality of life. And if your quality of life is allowing you to do everything possible that you want to, then treatment might create a worse quality of life, especially if you don't meet the criteria for treatment.
So what we want to do is make sure we have regular intervals of follow-up during this time. And it really depends. It's really on a patient-to-patient basis because if your counts are excellent and you don't meet criteria and you have no symptoms related to other findings such as splenomegaly, then one of the ways you may be followed is maybe a once-a-year annual checkup. But if those counts start to get a little bit more abnormal or they're changing, then that might go down to six months, every six months.
And if they go down a little bit more, then maybe it's every three months. But the idea is in that interval, you're going to have the ability to contact your team and let them know if something changes. And that's one of the main things that we want you to take back, is that please let your team know. Do not wait for the next appointment. Please let your team know if any of those symptoms that Kerry talked about—fevers, chills, night sweats, weight loss that is unintended, or symptoms from your spleen—are starting to change, then please let us know.
The Blood Count Dashboard: Knowing Exactly When It Is Time to Treat
So when exactly is it time to treat? So there's some strict criteria which can be symptom-based. So the sweats, the spleen. So one of the things I ask my patients is about, "Do you have any discomfort in your abdomen?" And for the most part they're like, "No, not really." But then you ask a little bit more. "Oh, I've been having some more heartburn recently." "Oh, that's interesting. Has your diet changed?" "No." "Are you having more acidic features?" "No." But one of the things people forget is as the spleen enlarges, it actually compresses the stomach.
And when it compresses the stomach, you can have symptoms such as gastroesophageal reflux disease or GERD. People can have discomfort where they can't sit properly. They start lounging back in their chairs, and they try to make themselves more comfortable because the spleen is actually taking up space, and you can't actually move your body in the same way. They also say they can't eat meals in the same way. "I can look at the food, I'm hungry, and then all of a sudden I'm full." So early satiety is also one of the symptoms of splenomegaly.
And so those are all symptoms that could affect your quality of life. And then there's the objective changes. These are the things where you're in a safe range, then we need to monitor as those numbers change and then where we take action. So Dr. Rogers had clearly put those numbers up. So if your hemoglobin's less than ten grams per deciliter or if your platelet count is less than one hundred. And then one of the key drivers of treatment, and what I think as a treater makes me nervous, is the neutrophil count.
I can deal with a hemoglobin, I can give you a transfusion. I can deal with the platelets, I can give you platelets. But the neutrophils are the scary piece because that's what puts you at risk of infection. So a neutrophil is your bacteria-fighting white blood cell. And it's often termed the absolute neutrophil count, or the ANC. And it's that kind of threshold of having less than one thousand per microliter, or one on your actual blood test, that makes us very nervous. So a lot of times it's the trend over time that is more important than the absolute value.
So, as your numbers are starting to get lower, we'll get more data points, and then we can kind of see what that trend looks like. And so some people are like, "But I feel well. I don't want to be treated." And their neutrophil count is going down, from 1 to 0.9, and then 0.8, and 0.7. And then at 0.5, I get very nervous, and that's where I was like, "You know what? I'm starting to get uncomfortable here." And a lot of it depends on what you're doing.
Someone who's retired and not socializing may have a very different exposure risk to infection than someone who's actively working as a schoolteacher in a primary school. And so that, when you decide to treat, actually may be different. So those are things to… it's really important for us to know you, and this watch and wait period gives us that luxury of time. But some people present with these numbers, and then we have to make those decisions quite immediately.
Phase 2: Pre-Flight Checks and Defining the Ultimate Goal of Your Therapy
So we talked about the goals of the treatment. And we are all trying to get rid of these abnormal cells, mainly to allow the bone marrow to have the function required to create the cells in a normal amount. And then hopefully reverse the symptoms by shrinking the spleen if that was one of your main symptoms, but normalizing your body to allow for that quality-of-life goal. But there are some simple things that we do want to test. We do screening for hepatitis to make sure that we don't cause more trouble, and if you need prophylaxis to protect against hepatitis, that can be given in parallel.
And then making sure that you have good bodily function with your kidneys, your liver, to be able to tolerate the treatments that we want to give.
Planning for the Unpredictability of Treatment
So I think it's really important, because we have a watch and wait period, that we're planning for unpredictability of treatment. So if you're working, you may need or want time off, and it's really important that you connect with your HR personnel to discuss sick leave, disability, things that might be accessible to you to make this journey better. If you're a young person of childbearing age, then we want to make sure that we have a plan for fertility. Now, what we understand is the outcomes of pregnancies in patients who have had hairy cell leukemia are actually very good.
But we want to make sure that you've had that consultation with the experts. When it comes to travel, I live in a country where my winters are minus fifty degrees Celsius, and all my patients want to come to Florida or Arizona in the wintertime. So travel is a really important thing for patients. And so how does this affect your ability to travel? What do you need to do to protect yourself? Are there challenges with insurability and receiving healthcare in the area that you're going to? And it's important that we have those discussions so we can set the expectations and there's no disappointment as a result.
So really important things. And then how do we support you through this journey? Everyone has good networks of people that they love and trust, but there are also resources such as psychosocial support that might be available through social workers and groups of people that can support you through the journey that may have lived experiences but also have the ability to help you navigate the systems as such. What I wanted to spend a little bit of time on, and I think Dr. Bhat's going to go into a lot more detail, is really the standard approach to care in patients with hairy cell leukemia. And so the nucleoside analog cladribine is probably one of the best treatments. It can be given in different ways in different jurisdictions. But it is an easy treatment to receive in terms of the delivery of the care. And basically it works by getting rid of the hairy cells. And in patients, a single course of therapy can result in eighty to ninety percent of patients achieving a long-lasting complete remission.
Case 1
So I thought I would try to highlight and illustrate things with some cases. I had a thirty-six-year-old male patient. His story is actually published online. He's a weightlifter and a provincial champion, and he came in because he could no longer weightlift eight hundred kilograms in his competition. So he's like, "I'd do my workouts, and then I would rest, but I wasn't recovering between my workouts. And I went down from seventeen hundred pounds, and I couldn't lift… I was only lifting twelve hundred pounds, and nothing had really changed." And so I had a new appreciation of fatigue in the definition because I had not seen someone who was so well and obviously so strong, and then all of a sudden… this reminds me that the definition of fatigue for everyone is different.
And so it really depends on what you were doing. So I don't think it's a great assessment to ask what they're doing now. You need to know what they were doing two years, five years before, and how that's changed over time. So this gentleman received cladribine rituximab, had an excellent clinical response because I didn't do a bone marrow to do the CR, so I can't call it a complete remission. But he's back to competing, and six months after he completed therapy, he was back to lifting his seventeen hundred pounds.
First-Line Induction Therapy Protocols
Depending on where you are in the world, what treatments you have available in the front line might be cladribine or pentostatin. I know there's a shortage of pentostatin now, so I think a lot of people are receiving cladribine. It's often given as a single agent. It can be given intravenously or subcutaneously, and it's found to be effective regardless of the route. But what things differ is that sometimes it's given as a continuous infusion over five days. It could be seven days. But then there are some groups that have also been giving this as a weekly infusion to minimize the cytotoxicities, especially in older individuals, and that's something that we do at our center.
The Synergy of Combination Therapy: Two Paths to Deep Remission
The other thing that has been done is that we know that cladribine's effective as a single agent, but there are some people who have shorter responses to single-agent cladribine. And so a lot of work has been done through the research that has been funded by the Hairy Cell Leukemia Foundation on evaluating the effect of combination therapy by adding an anti-CD20 monoclonal antibody such as rituximab. So sometimes this can be given as a combination with the two drugs together, or it can be given where the cladribine's given first and then there's a delay and the rituximab has been given different.
I think from what I take away from this is that this is a very powerful therapy. It can lead to longer remissions. And it is very tolerable as a treatment. But there's always things that we need to think about. The complete remission rates are extremely high with this treatment, and very few patients will relapse, and the long-term survival is excellent.
Tailoring the Journey: Adapting Therapy for Age, Fitness, and Active Infections
And so who would you pick one or the other for? And I think there's some things that we need to think about: the bulk of disease, what are we thinking of in durability of response, and who are the patients that are best suited for this? So you might want to think of my 36-year-old patient. He's going to need multiple lines of therapy in his lifetime, so why don't I give him the best treatment I have available, which would be the combination. But then, I saw a 76-year-old person, and they were very fit, and I did the same thing.
But there might be someone later on that has more advanced age, and as a result of their other medical conditions, I might choose to give them a single agent, but I would have the conversation with them to ask them what they think. And that's where we have to think about the older, frail patients, and we might need to compromise efficacy for tolerability, and that's where the single agent may be better. And then we talked about patients with active infections. So we do have tools to support them, but we might take a different route, maybe start with a non-chemotherapy-based treatment such as vemurafenib or a targeted agent to bridge through that infection period, clear the bone marrow, and then go back to our treatments with the chemoimmunotherapy.
Prophylaxis During Treatment
So there are things that we might need to help patients through the treatments and prevent infections, and this comes in the shape of antibiotics or antiviral therapies to prevent severe pneumonias that patients who are immunocompromised get, such as PJP pneumonia, which is often seen in HIV patients, as well as shingles. There are other toxicities that we need to worry about, and that is rashes. And that can happen because we're giving concomitant medications. Allopurinol is often used in cancer treatments to prevent damage to the kidneys to allow for treatment to go on board, but has a really high risk of creating a rash in patients who receive cladribine, so may not be the best idea unless you really have significant bulk of disease.
And then that antibiotic that we use is a sulfa-containing drug, so some patients can get the same skin reactions as a result. And so then we're trying to figure out: Is it the cladribine or is it the Septra or is it the allopurinol? So these are just things that, if we empower the patients to ask those questions to their providers, they may have a better outcome.
Phase 3: Navigating Side Effects as Your Body Rebuilds Its Defenses
The last things that I think are really important are that these treatments do lower the blood counts before they make them better. And so one of the things that we need to work on is how do you prevent infections because of this. I think it's really important that patients will become fatigued, maybe even a little bit more as they're going through this journey. But I always say that your body is doing invisible work that you have no idea about. It's actually repairing everything that has been damaged and trying to make new blood cells, and those are energy-consuming processes, so it's okay to feel fatigued.
But my hope is at the end of the treatment, and that might be four, six, maybe even three months after, that you're way better than you were when we started. But it's really important to understand that, and that's why taking the time is important. You might need some antihistamines to prevent infusion-related reactions. You also might need transfusions to help with the blood counts during your treatments.
The Danger Zone: A Fever During Treatment Is a Medical Emergency
But I think the most important thing I want to tell you about is that if you develop a fever, it's really important that your team knows about it. And some people have specific thresholds. Some of the recommendations say a fever of thirty-eight, and my institution (Cancer Care Manitoba, Canada) is thirty-eight point five. But if you have a fever, contact your team because we know that if we get antibiotics into the system faster, then the outcomes for patients are better. And so really important that we know that you're immunocompromised. We're actually immunocompromising you more with our treatments, and we really need you to connect with your team so that you can get the best care possible.
We'll do blood cultures. We'll do chest X-ray. We'll check your urine, make sure you're not growing anything. But in the meantime, while we're waiting for all those results, we're going to give you antibiotics to protect you.
Patient Case
And in this case, I had two patients that I was treating over the summer this year. One whose blood counts had gotten down, and she developed a fever. We held the treatment for a week, but the neutropenia didn't really get better. So we decided to give her a hormone that boosts the neutrophil count up, which is the granulocyte-stimulating factor, and she was able to go through the rest of her treatment, no problem. I had another young lady that actually developed fever and was neutropenic and she was in the middle of her treatment, but her blood pressure really dropped.
She was fine otherwise, but her blood pressure really dropped. And so she needed to be admitted to the intensive care unit because of her low blood pressure. And in her, I was a little bit nervous to continue the cladribine and the rituximab, so I gave her vemurafenib, and her counts improved so quickly. And then we consolidated her back with the cladribine rituximab.
Building Your Protective Shield During the Vulnerable Recovery Weeks
What we're trying to do is make sure that you're well-protected, and this is called the protective shield. There's multiple layers to that. So during your treatments, we need to give you medications to help support this. We might need to give you blood products or hormones to help improve that blood production. And then the responsibility that you have while you're receiving your treatment is the exposures that you can actually control. So if you're in crowded places, masking is important. If you're traveling, you may want to wear a mask on the plane.
And making sure that sick visitors aren't coming to you and ensuring that there's hand hygiene. I always tell my patients, at your front door, there's a sanitizer bottle. Everyone washes their hands, especially if you're on therapy, and you're not allowed to see your grandchildren if they're sick, and no sick people should be visiting you.
The Vaccine Rulebook: Protecting Yourself With the Right Timing
And then we talked about the vaccines already. The challenge is if you're about to get treated and you can be delayed, we always recommend the vaccines are done at least two weeks before. But if you've already started treatment, then vaccinating after is appropriate.
Mapping Emerging Targets in Variant Disease
One of the things that I think you'll hear a little bit more about is the traditional standard treatments, especially with single-agent cladribine or cladribine rituximab, are excellent for hairy cell leukemia. But if you do have a variant, the combination may be better for you. But we're in an era where now we're starting to use molecular techniques to try and understand the biology of the disease better, and there might be some mutations that carry resistance to those standard treatments. And as a result, different treatments might be better.
Phase 4: Life After Therapy and the Return to Normalcy
So, what are we trying to do after you've completed your treatment? I think because we know the remissions on average from these treatments are anywhere from seven to fourteen years, the initial kind of part is first waiting for your body to recover, and this takes time, right? Your red blood cells need a hundred and twenty days to turn over, so that's four months. It might take a little bit of time for the blood counts to get to where they need to be. And it's three to six months after treatment where you might start feeling your best.
But because we're at a point where the overall survival for these patients is so high, you're going to be living with this condition. And it's still important to live life to the fullest independent of that. And so we're really trying to make sure that you have all the tools and the guides to be able to do this with the Hairy Cell Leukemia Foundation, and also the psychosocial support that you might need to adapt to that change in mental status. Because at some point there's always going to be the fear of relapse, but the reality of the situation is the outcomes are usually very good.
And now we have a little bit more tools that we might be able to help people predict, are they going to have a short remission or a longer remission? And there's a lot of research being done to go there.
Your HCL Survivorship Summary
This is the summary of what we talked about. Wait wisely. Treatment is a deliberate choice because of the thresholds that we've met. We want to make sure that you receive the best treatment possible. And we want you to partner with us in the protection. Some of it we can help and guide, but those choices are yours, especially when it comes to vaccination. But we need your help to also carry something that tells them that this is the diagnosis. You might be presenting to a center, you might be on a trip that might not have the information at their fingertips.
And you're equally empowered to do so. And like I said, live life to the fullest. So with that, there's a series of references at the end of my presentation that were used to develop these slides.
This transcript has been edited for clarity.
-
Preparing for Treatment and Recovery
Questions and Answers with Dr. Versha Banerji
If remissions can last many years, why might someone diagnosed at a young age need several treatments during their lifetime?
Dr. Banerji: So I think it's because of the early age of onset. So when Dr. Rogers presented her data, she said the average age is 55, but the reality is that you have some people at either tail.
So unfortunately, because we say the response on average is 7 to 14 years, even if my 36-year-old gets the maximum advantage, that's 14 years out, and he's only 50. At that point in time, there's going to be a need for another treatment. And if we're saying the life expectancy of a human is 84 to 86 years, that could be three treatments by that time.
There are some people who don't relapse, and that's the reality of the situation. But we heard from our president today and she's one of the few folks that I've seen, who was young and then has had a few treatments down the line. And so I think it really depends what risks you have, and there are some molecular phenotypes that might drive that.
Some of the mutation testing that we look at is the family of the immunoglobulin heavy chain, and some of those folks may have shorter remissions. So I think the best thing is when you get your diagnostic toolkit, we'll use some of that information to predict the response. We're doing some research to try to create a calculator to figure out who should receive cladribine, who should receive cladribine with rituximab, and maybe what those outcomes will be.
But I think the rule would be that if you're younger, because you're going to live longer—I don't think that differs with any disease that is chronic and incurable. So CLL has those same rules, where you're bound to receive another treatment because the treatment lifespan is limited. But there are those folks that can potentially be cured by one treatment or maybe a second treatment.
But we're still learning who those people are and may not be able to give that information to every patient when we see them.
Why was polio included on the vaccination slide, and what should people with HCL know about live vaccines?
Dr. Banerji: So the main reason that's up there is that those are standard vaccinations that people should have had as they were growing up.
And there are boosters for some of the vaccinations that occur at time points, and primary care folks do it. We do have populations of folks that may be anti-vaxxers as well. And so we try to ensure that we do things in a safe way. When people are younger they're often not diagnosed with this condition, and live vaccines are a challenge.
One of the things that we want to do is ensure that they have those measles and polio vaccines when they're younger. But we've been having a lot of measles outbreaks recently, and so we're coming to the questions around, “Should I get a measles vaccine or not?”
And this is something where we know there might be a risk because of the live vaccine. And in some cases, titers can be measured, and if you have the titers, you might not need the vaccination. And then we educate the patient if they don't have the titers around the risks of the live vaccine.
But ultimately, it's a choice that they can make. If they're in a safe space where they're not currently being treated and their neutrophil counts are in a safe range, then, there's probably less risk with the live vaccine at that time. When shingles was a live vaccine, we did see patients have shingles as a result, which is why the non-live vaccine is recommended.
Not every jurisdiction has access to that. And it's something to think about. So in that case, those live vaccines need to be done with caution.
Can antibody titer testing help determine whether I need a vaccine or still have immunity after treatment?
Dr. Banerji: Yes, I think so, if you can access a test. Sometimes the titers may not correlate with protection, and that's something we learned with COVID as well. But I think it's the best tool that we have to assess that.
Are antibiotics given routinely during treatment?
If fever or sepsis develops, how is it treated, how quickly do antibiotics work, and might hospitalization be needed?
So in patients who have normal counts and are not on treatment, they could still have a risk of infection. And there's one thing I didn't touch upon in this talk, which was we make antibodies to fight infections, and sometimes those antibodies are lower than expected. And as a result, people can have repeated infections, and the most common is IgG or immunoglobulin G.
And so if those levels are really low, you might be at risk of repeated infections. And in that case, you might need other supports such as immunoglobulin replacement or antibody replacement to help fight infections. So that's always something that we keep in the back of our minds: if someone's really getting repeated infections and their counts are good, why is that happening?
So that's one solution to protecting yourself. While you're on active therapy, certain drugs have known risks of immunosuppression. And because they're immunosuppressing you to the point similar to a patient with HIV, you would get antibiotics to help prevent those infections routinely on therapy.
At least in our centers, we would give the PJP prophylaxis and the antiviral for shingles if you're getting cladribine or pentostatin-based treatment. And that's usually done for the duration of treatment and maybe up to four weeks after. But once that is complete, you're off. If despite receiving those prophylactic antibiotics and antiviral therapies, you develop a fever on treatment, then that is when the alarm has to sound, and you need to contact your primary care provider.
Our hospitals have protocols for people who come in with febrile neutropenic episodes, so you can just present to the emergency department if you've measured a fever. We also have urgent care facilities that can do the same things, so you're not clogging up emergent areas, and that is specifically for after-hours and weekend care.
If you're in clinic, we have urgent care in our clinic, or you can contact your clinic team and they will investigate you there on the spot. Whether you're going to be admitted to hospital really depends on how sick you are. There are patients who are perfectly well that present with this and can be treated as an outpatient without admission to hospital.
But if your blood pressure is low or you're developing symptoms like cough, things like that, then it depends on what supports you need as to where your treatment will occur. The antibiotics work pretty effectively pretty quickly. So the sicker you are, the more chance you're going to get intravenous therapy, and that's getting into your system right away.
But even as an outpatient, you're given antibiotics sometimes two to three times a day, and as a result, you're taking your first dose as you're seen, and then you're going to maybe take the next doses after. And people often feel better within twenty-four to forty-eight hours of receiving the antibiotic therapy and can actually feel the difference.
And the challenge is that if we wait too long to give the antibiotic, then the load of the bacteria in the system continues to increase and as a result, you might have poor blood flow or poor blood pressure. And what we're worried about is the organs kind of shutting down because of that and the infection taking over.
So the idea is to get the antibiotics in, kill off the bacteria so that you don't end up with that situation.
Does giving cladribine and rituximab together increase side effects or infection risk compared with giving them separately? When is it safe to be around people again?
Dr. Banerji: Those are very good questions. I think there are some philosophical differences on how the drugs are delivered.
But if you can imagine, they're working in different ways. So the challenge with both cladribine and rituximab is that they have an effect on your healthy cells. So when you're only getting one of them, that effect is likely less pronounced than both together. And we know that getting an antibody against CD20 has very long-lasting effects of immunosuppression over time, even after treatment is completed.
Usually, when the cladribine is done, at least the effects on the healthy bacteria-fighting white blood cells and neutrophils are removed after that. There are some effects on other types of immune cells that can still lead people to have risk of infection after treatment. And because we've given you antibodies that are directed against your B cells, which produce your antibodies to fight infections, you can still have some immune suppression afterwards. When we look at the combination together, the risk of having the counts drop at the same time might be higher. So you may not choose that combination for someone older or frailer because the risk of the counts dropping is higher.
But everyone's body is different. We usually have a bone marrow ahead of time to help us. And because of that, you may choose the combination because people have enough of the ability to rebound from the treatment. But when we do the cladribine alone and then give the rituximab after, sometimes the cladribine helps get rid of the cancer cells and then boost those counts up so that you're better able to tolerate the combination together.
So at my institution, we do it even a little bit differently because we're not giving the cladribine every day for five days. And part of that is if you think of a public healthcare system, every admission to hospital because they've had a neutropenic event is a resource-intensive issue, and it requires a lot more support.
So if we can keep people in the outpatient setting, and there's really no race to get people treated, in all honesty, and you want to do it in a safe way, we actually give the cladribine weekly. And then we do that for two weeks, and then we add the rituximab, and we give it every week thereafter. So it's a little bit different than what's done, and part of that is to help people have fewer events over the time period.
And so it really depends on your institutional standards and norms. But the philosophy around the treatment is similar in that hopefully you mitigate those challenges. And sometimes that gap can be from one month up to six months in some of the clinical trials of when the rituximab has been added. And sometimes they're measuring the level of depth of response and adding based on that residual disease factor.
So it really depends. A lot of those data come from studies. But in clinical practice, the standard would be the weekly cladribine and then the rituximab sequentially thereafter or in combination at the same time. But I think we're weighing the patient in front of us as to what we would want so that they have fewer events.
So I guess the conclusion is that there is no clear answer.
What is the longest period you have monitored someone with HCL before they needed treatment?
Dr. Banerji: So this is where I made the comment that if you're in the medical system for a different reason, sometimes you're picked up incidentally as a result. And it's not because of the hairy cell leukemia that you were picked up, but someone's going for knee replacement surgery and had a blood count done because of that, and then all of a sudden the blood counts are not in the range that was expected.
And so technically, those patients may not meet the threshold for treatment, and so they were diagnosed based on another reason why they were in the healthcare system. But my experience actually is most of the patients coming to me are coming because they need treatment because they were symptomatic with low blood counts or fatigue or bruising or repeated infections.
In my experience in my practice, I think the watch-and-wait periods are less common.
Additional panelist: Just thinking of my experience, and this is before initial treatment, right? For sure eleven years for someone. I think I have someone that actually might be a couple of years like before that too without needing treatment, but I can think of someone that's at least eleven years.
Additional panelist: I will talk about a different kind of watch and wait here. So I have a few patients in my clinic who actually do meet indications for treatment. But Dr. Rogers did mention a platelet count hovering around 90, 85, 99. So technically, if you go by that 1, 10, 100 rule, they are below 100,000 and do meet indications for treatment.
But there, what we do usually is you look at a trend over time, and if you see the trend is down to 90, next time it's 80, and continuing downward, you definitely do a treatment at that time. But I have a couple of patients who have been bouncing around 90 or the high 80s, and I have been watching a patient and that patient has been very reluctant to start treatment, and he feels good, and he's bouncing around that range, and I've been watching him for more than five years now.
Yeah. And then there's another patient who met criteria for treatment. He was in that 70 range or high 60s but didn't want to do chemotherapy. He wants to do vemurafenib-based treatment, but he does a lot of outdoor work and is concerned about phototoxicity, and he wanted to start treatment in the winter months.
So he'll be coming somewhere around January to start treatment. So again, patient preferences, lifestyle, other things need to be taken into account.
Additional panelist: I agree with Versha that I have, in certain patients, used a weekly approach with cladribine. And in my opinion and experience, it is safer.
Because when you give all the cladribine at once, you tend to have a higher chance of having lower counts for a short period of time. We also have known that patients who have an active infection should be considered for a different approach, as you pointed out. And we've had patients who have been able to be rescued from the infection by using a BRAF inhibitor.
But also I would point out with pentostatin, I've treated patients with an active infection and been able to get away with pentostatin. And I think the reason for that is that it's delivered as one dose every fourteen days. And so the counts don't tend to go as low as they do when you give all the chemotherapy in a five or seven-day period.
But that's also probably one of the reasons why I would agree with you that it may be a little bit safer if you have a fragile patient, if you're going to give them cladribine to maybe do the weekly approach. The other thing I would point out that you've already pointed out is that after the chemotherapy, whether it's cladribine or pentostatin or either one of those in combination with rituximab, it takes quite a while to get recovery of the lymphocytes.
So it can sometimes be up to a whole year before patients have recovery of their lymphocytes. And during that time, I usually follow the CD4 counts on patients. And that gives you some idea when the immune system is recovering. I've been doing it for a while, so I've had a couple of people that have had really serious consequences from shingles if they don't have adequate protection long enough and that some of those complications can be fatal.
One of the things I also do is I measure the gamma globulins, as you pointed out, because I have had patients who have had hypogammaglobulinemia as a result of being effectively treated for the hairy cell leukemia. So then they have a second problem: you have to be careful about bacterial infections.
And if you follow the patients, and if they have a seriously low immunoglobulin G level, you know that they are good candidates to get antibody replacement—or immunoglobulin replacement. But the specific question that was asked was, "How long have you... What's the longest period of time," right? So I've been doing it for a while, so probably the longest I've ever followed somebody was for 18 years before treatment. So they never met the criteria, specifically hematologic parameters. However, I wish that I was able to treat the person because they've had other complications of the disease, but this individual has had eight serious squamous cell carcinomas of the skin, and they've also had eight basal cell carcinomas of the skin.
And before we were dealing with the hairy cell leukemia, they had been treated with immunosuppressive therapy for another condition, and one of the squamous cell carcinomas became invasive. When you're dealing with somebody with a proclivity or tendency to have a lot of squamous cell carcinomas of the skin, you have to be aware that the drugs that we use to treat hairy cell leukemia further suppress the immune system.
This person had invasion of one of his facial nerves because of immunosuppression delivered for another reason. So it's really been a dilemma, but his hematologic parameters have never been low enough to mandate active treatment. And so the other problem is the BRAF inhibitors are very effective because they're not as immunosuppressive, but there's an increased incidence of skin cancers.
So one of the things I'm considering is if you use a BRAF inhibitor along with a MEK inhibitor, maybe a lower incidence of infection. And then hopefully with Seema’s upcoming protocol with a new agent, it may be able to prevent some of the conditions that give rise to secondary cancer.
Now, the other thing I would point out though, is that this is one patient over about 4 four years worth of treating hairy cell leukemia. So 10% of patients with hairy cell leukemia don't need to be treated immediately, but ultimately, the overwhelming majority has to be treated.
And when you ask the question, “How long?” it also depends on whether there is a contraindication to treating. You have to factor that into your decision about when you're going to treat.
Additional panelist: To be fair, we don't actually know that treating the hairy cell leukemia will make the skin cancers less likely.
And we had a very robust discussion with the hairy cell physician expert group and nobody knows the answer to that for sure.
What does the research tell us about HCL and the risk of other cancers?
Dr. Banerji: So the reason I put up the screening information is that there have been some data to suggest that patients with hairy cell leukemia are more prone to secondary cancers. And that might be independent of the treatment type, because we saw some data from different centers where the hairy cell leukemia was being treated either with cladribine or cladribine/rituximab.
We had some patients being treated with fludarabine and rituximab. And interestingly, the commonality across the group was that there was this incidence of second cancers. Now, I think what we require a little bit more data on is the timing of those second cancers relevant to diagnosis and treatment.
Because we do know that some of the immune suppression from treatment can lead to second cancers. That seems to be more common in other B-cell cancers compared to hairy cell leukemia. So it might be the disease itself in hairy cell leukemia that is actually creating that excess risk.
Additional panelist: Yeah, I think the important thing to note here is that your immune system is what protects you from other cancers.
So if your immune system is not functioning optimally, it will not kill cancer cells in your body as well. So it's not that the hairy cell turns into skin cancer, it's just your body can't protect you as well because your immune system's not functioning the same.
This transcript has been edited for clarity.
Treatment Today: Making Sense of Your Options
Dr. Seema Bhat, The Ohio State University
-
Dr. Bhat is a hematologist-oncologist and associate professor at The Ohio State University Comprehensive Cancer Center. She specializes in the care of patients with chronic lymphocytic leukemia, hairy cell leukemia, and related blood cancers. Her work includes evaluating targeted therapies, helping patients navigate treatment decisions, and contributing to clinical research to improve outcomes and quality of life.
Dr. Seema Bhat explains how doctors decide when to treat hairy cell leukemia (HCL) and how they choose among treatment options. She compares established treatments with targeted medicines, discusses how side effects and personal preferences can shape the decision, and shares what researchers are studying in clinical trials.
Key takeaways:
Some people can start with monitoring blood counts and symptoms over time to decide when treatment may be needed.
Your health and preferences help shape the plan.
Cladribine and pentostatin remain important treatments for classic HCL.
Targeted medicines can be useful in selected situations.
Clinical trials are exploring more options.
Bring questions to your doctor’s appointment.
View a recording of Dr. Bhat’s presentation below.
-
Treatment Today: Making Sense of Your Options
HCLF Patient Seminar 2026 | Speaker: Dr. Seema Bhat, Ohio State
Thank you all for being here today.
When Is Treatment Needed?
We did discuss that treatment is usually recommended for most patients with hairy cell leukemia at some point in their disease journey. About 10% of the patients may not require treatment right away, but mostly over time they will go on to progress to require treatment. It was fascinating to hear that Dr. Grever has a patient who has not required treatment for 18 years, so that's wonderful to hear. But if you give treatment to these patients who don't have symptoms to start off with, you will just give them the side effects from the medications, and these are not medications that are devoid of adverse events.
So you don't want to take completely asymptomatic patients and make them sick. So we really wait for those indications to develop before we start treatment. And Dr. Rogers discussed those this morning. To recap that, we look at the blood counts first and we go by that 1-10-100 rule. One means neutrophils below 1,000, hemoglobin below 10, and platelets below 100,000. We usually look at the trend over time, especially with platelets. Again, Dr. Banerji discussed symptoms of an enlarged spleen. Just having a spleen that you see on a scan or on an ultrasound or a CT scan does not mean that you need treatment.
The spleen has to be symptomatic, and Dr. Banerji excellently described those symptoms as early satiety, or you may feel full. You may have food in front of you, but you cannot eat. You get full very easily. That's what your doctor will call out, "Do you have early satiety?" Or you eat, you change your pattern of eating. You used to eat one big meal, but you cannot eat a big meal anymore. You eat smaller, frequent meals throughout the day. So pay attention to those. If you have those symptoms, these are symptoms of an enlarging spleen.
Again, lymph node enlargement is not very common with hairy cell leukemia, but you can have that. And as Dr. Rogers discussed, very rarely you can have bone lesions. I recently had a patient who had a lung lesion, lung involvement with hairy cell leukemia. So those are unusual, but sometimes you can see those. And then we described those symptoms of profound fatigue. Again, it's not that you have the flu and you are fatigued for a couple of days. It's profound fatigue that is continuous for a long period of time, and that interferes with your daily activities.
You just want to lie in bed, sit down, don't want to do anything, like even basic things that you do for yourself. Or you have persistent fevers, night sweats that are drenching through your nightdress or your sheets, making them wet, or weight loss which you cannot explain by any other reason. If you're on Ozempic, then you have a reason for that weight loss. And you don't have to have all of these. You can have one or more of these indications for treatment when your doctor will discuss with you that we have come to the point that treatment is needed.
Choosing a Treatment: What Matters?
Then the discussion about the choices of treatment will start. And when that discussion is made, there are a few things that are done before the discussion of the treatment is held. You will most likely get a bone marrow biopsy because that's where the hairy cell leukemia originates from. And you will have your baseline blood counts done. You will also have other testing done to see how your kidney function is, liver function is, and your other medical history.
Do you have a history of frequent infections, a history of kidney disease? Because this all impacts what treatment choice will be made. For example, infections are big with hairy cell leukemia. The risk is there because we discussed neutrophils can be low. Neutrophils are our infection-fighting cells, the first warriors that come to fight infection when we encounter bacteria or any other pathogen. So if you are low on your neutrophils, you are prone to get infections. If you're someone who gets serious infections, frequent infections, or you are presenting with an infection, we have patients who get admitted to the hospital, are found to have a bad infection, a bloodstream infection, or a bad pneumonia affecting both lungs, or even a fungal infection, and we find out that their neutrophil count is very low, like 200. Their infection is not going to get better without treatment for their hairy cell leukemia.
Yet there are treatments that can further reduce that neutrophil count, and you can make the infection worse by giving that treatment. That's where you have to make the choice very carefully. Those patients may not be right candidates for cladribine because you give a big dose of chemotherapy over five days, and you cannot undo that effect. So that's where we can use the gentler agents like vemurafenib as a bridge. It has been seen that vemurafenib does increase the neutrophil count and other counts pretty quickly within weeks' time so that your neutrophils will improve, and you'll have adequate neutrophils to fight off that pneumonia or that bloodstream infection or that fungal infection, and then you can get to the point that you can receive cladribine or other treatments that are more definitive for the hairy cell leukemia.
So these choices are very individualized, and we always take these into account. We also look at how hairy cell leukemia is affecting you. Are you getting frequent transfusions? And also, what are your preferences? You discuss the treatment, how it's given, the duration of treatment, like cladribine, five days and you could be done. Seven days, you could be done. Dr. Banerji discussed the weekly cladribine, a subcutaneous cladribine. There's also research going on with oral cladribine. So discussing the schedule of treatment, there's a difference with how vemurafenib is given. There's a difference in how pentostatin is given.
And how that sits with your preferences, what you would like to do, and that's when we make the informed decision. And also, what side effects do these treatments have? Because these agents come with different side effects. And discussing the side effect profile, that can also impact the decision of what treatment will be the most right treatment for you and for your individual case. So most of the treatments that we have today fall into different categories.
The Main Treatment Options
So the time-tested, age-old treatment is the classical chemotherapy. The chemotherapy that we have for hairy cell leukemia that works very well, these are called purine nucleoside analogs. We heard about them this morning, and there are two that are effective. We have cladribine, and we have pentostatin. As we said, patients can get 10 years with the frontline treatment, but most patients do end up relapsing. And you can get another course of cladribine or another course of pentostatin. And we sometimes, and oftentimes now, combine them with another agent called an anti-CD20 antibody, most commonly rituximab.
Then we have non-chemotherapy options for patients with hairy cell leukemia. We have the BRAF inhibitors. The most tested one is vemurafenib, but we have some others also. We also have BTK inhibitors. We have data on ibrutinib, but there are other BTK inhibitors also which are approved for other diseases, which may have a better side effect profile compared to ibrutinib and can be used for hairy cell leukemia. And there are multiple agents that are in clinical trials. We talked about vemurafenib. Vemurafenib has a specific side effect profile, so we are always trying to see if we can have a better vemurafenib-like medication.
So we have other BRAF inhibitors in clinical trials. We have another agent, another targeted agent called venetoclax, which is a BCL-2 inhibitor in clinical trials. And we have other agents like CAR T-cell therapy and bispecific antibodies that work through the immune system. These are also in clinical trials. And then sometimes there used to be age-old treatments like interferon and splenectomy. Sometimes very rarely we can get into situations where we may have to use these treatments, so we have not discounted them completely. There may be occasional indications for these treatments as well. Very rarely, though.
Cladribine and Pentostatin: Common First Treatments
So coming to cladribine and pentostatin, which are the purine analogs, these are the mainstay of treatments even today.
These are the common first treatments. And how these treatments work is that they interfere with how leukemic cells make their DNA. Both these drugs have not been compared head-on, but they can both individually lead to long remissions in hairy cell leukemia. The main difference is how these medications are given. For example, cladribine, we learned this morning, can be given as a continuous infusion for seven days, or it can be given daily for five days over two hours each day. Or we can even give it subcutaneously.
We can give it weekly. We dose reduce and give it weekly. And there is an oral formulation that's also in clinical trials. But short treatment, five or seven days of treatment, and you're done with it. On the contrary, we have pentostatin, which is also a purine analog, a nucleoside analog. It is given every two weeks until you get into a remission, which can be in four months, which is eight doses, six months, which is very variable for different patients. Again, different situations that you use these drugs. For example, cladribine in a patient who's acutely sick, having an infection, I would like to avoid cladribine for those patients.
Pentostatin can be used in those situations because you're not giving a big dose at one time. You're giving the drug in smaller doses divided into every two-week doses. And you also have the luxury to dose reduce from four milligrams per square meter; you can go to three or two milligrams per square meter based on the situation that we encounter with different patients. So, these treatments are very effective.
How Well Do These Treatments Work?
Both these treatments lead to complete remission, as Dr. Rogers defined this morning, that the counts have recovered and the bone marrow has no evidence of disease. About eighty percent complete remission rates, and these remissions can last for over ten years. That means you can get, with one cycle of treatment with cladribine or four to six months of treatment with pentostatin, you may not need treatment for another eight to ten years, which is remarkable. And again, if you need treatment, these agents can be repeated. And it was these agents which led to the lifespan of patients with hairy cell leukemia being almost comparable to a normal population.
Why Add Rituximab?
So this was a really big change in the natural history of hairy cell leukemia. Now over time, we learned that this drug, rituximab, which is a drug that binds to an antigen on the surface of these lymphocytes called CD20, it binds to CD20, and what it does is it makes the chemotherapy work better. So together they work better. And it was first shown in the relapsed setting that it led to better CR rates and better responses. When things work better in the relapsed/refractory setting, then we try to move them frontline.
CDAR: Cladribine and Rituximab
Can rituximab be added to cladribine in the frontline setting to improve responses? Again, because they work better together, there's synergy, they improve each other's effect. There was rationale to do so. And we have a study where it was done in two different ways, where cladribine and rituximab were started together. We call it the CR regimen or concurrent cladribine rituximab. And it was compared to a regimen where you got cladribine first, and the rituximab could be delayed to six months based on if you still had disease at that point.
So not everyone got rituximab in the delayed arm, it's only those patients who had disease. And again, we showed that in the concurrent arm where it was given together, there were higher complete response rates and undetectable response rates were very high with the concurrent arm.
BRAF Mutations in Hairy Cell Leukemia
One of the major things that happened in the discovery of hairy cell leukemia is the discovery of this mutation, BRAF V600E mutation, which was discovered in 2011, which completely changed the way we looked at hairy cell leukemia. About ninety-five percent of the patients with hairy cell leukemia do have this mutation, and we call that classic hairy cell leukemia. And we at that time had a drug called vemurafenib, which does target this specific mutation.
Vemurafenib: A Targeted Pill
This was a drug used in malignant melanoma, and since this mutation was seen in hairy cell leukemia as well, they did clinical trials and saw that it was effective in patients with classical hairy cell leukemia also. And one of the remarkable things with vemurafenib is that it improves blood counts very quickly. So we talked about those patients who are profoundly neutropenic, have an infection; you cannot do cladribine in those patients. Yet those infections won't get better until we treat the hairy cell leukemia. That's where vemurafenib is very effective.
It does improve the neutrophil count quickly. The response rates with vemurafenib are high. The problem with single-agent vemurafenib, that means you use it by itself, is that the responses do not last that long. So to overcome that problem, vemurafenib was combined with rituximab.
Vemurafenib + Rituximab: A Combination Approach
And again, here they showed that when it's combined with rituximab, we had high response rates, and they lasted long, especially in patients who had MRD negative or where no hairy cell leukemia was detected and in patients who had not received the vemurafenib previously. Again, this study also showed the blood counts recovered very quickly. Platelets recovered in two weeks, and neutrophils recovered in four weeks, which is very important in patients who are having an active infection. Now this was all in the relapse setting.
Frontline Vemurafenib + Obinutuzumab
Again, we talked about when things work in the relapse setting, we try to move them into the frontline setting.
So this is a study where vemurafenib was combined in the frontline setting with another CD20 antibody, an anti-CD20 antibody called obinutuzumab. And we have data to show that obinutuzumab may be a better anti-CD20 antibody compared to rituximab. So here patients got vemurafenib for four months, 16 weeks, and obinutuzumab, a total of five doses of obinutuzumab over a three-month period, three-cycle period. And complete response rates, again, very high, 90% complete response rates.
And most of these patients, 96% of the evaluable patients, had MRD-negative disease. So highly effective, very deep responses, and we have eight years plus data available at this time. We have the author of this study right in this room, Dr. Park there. It's eight years plus, and no patient has relapsed yet.
BTK Inhibitors: An Option in Some Situations
So, the next agent is a BTK inhibitor. The one that has been tested and published is ibrutinib. BTK inhibitors are drugs which target this molecule, Bruton's tyrosine kinase, and actually these drugs are approved for many other B-cell malignancies like CLL. They completely changed the treatment paradigm for CLL. We don't treat CLL with chemotherapy anymore. Don't know if that will translate one day to hairy cell leukemia or not, but that's the hope. It's also used for mantle cell lymphoma, marginal zone lymphoma, and some other lymphomas, and has been very effective. These are very easy to take, taken by mouth. The problem is when you have to take BTK inhibitors by themselves as a single agent, this is continuous treatment.
This is across the board for most of the diseases that I talked about, CLL, mantle cell lymphoma. You take them, the reason being is that they're very effective in controlling the disease. Your symptoms will get better. If you have splenic enlargement, that will improve. The problem is the CR rates are low, the complete response rates are low, so if you take them off, the disease will come back quicker. There are other BTK inhibitors besides ibrutinib. We have acalabrutinib and zanubrutinib, which may be preferred because ibrutinib was the first-generation BTK inhibitor.
Even though it's very effective, it was associated with a few side effects which are very important. For example, it had effects on the heart. It can cause increased risk of bleeding. So we have these second-generation BTK inhibitors, acalabrutinib and zanubrutinib, which are very effective and have fewer of these side effects. So these may be preferred over ibrutinib. This was a study, again, Dr. Rogers is here in the room.
What Has Been Seen With Ibrutinib?
This was a study published by her in patients with relapsed/refractory hairy cell leukemia, including not just classic hairy cell leukemia, including variant hairy cell leukemia. Variant hairy cell leukemia is the one that does not have the BRAF V600E mutation. And again, we have five-year plus data. Progression-free survival was 68%, and about 87% of the patients are still alive at this time with ibrutinib. Again, the study showed the CR rates were low, that's why it has to be taken in a continuous fashion. The other treatments that are currently in research, for example, you might have heard for other diseases, we harness your own immune system, which is usually T-cell based. We have B cells and T cells in our body, the lymphocytes. We use the T cells, patient's own T cells, to attack the cancer cells. For example, one of the treatments is CAR T-cell therapy. You might have heard about that. Chimeric antigen receptor T-cell. What we do is we take out patient's T cells, we engineer them to express an antigen that is expressed on the hairy cells. For example, CD22 antigen is heavily expressed in the hairy cells, on the surface of hairy cells.
We engineer these T cells so that they express this, then grow them, and then give them back to the patient so that these T cells, now these engineered super T cells, can go after the hairy cells wherever they go. Wherever they find them in the body, they go after them and kill them. And these are currently in clinical trials. There are other clinical trials also ongoing.
Clinical Trials: How New Options Become Available
The hope is that one day we may again go the CLL route where we are treating patients with targeted agents. But so far we do not know whether targeted agents are better than the cladribine-based treatment, the CDAR treatment. So we have clinical trials that are actually comparing vemurafenib plus obinutuzumab in the frontline setting with cladribine plus rituximab in the frontline setting. This study is being done, it's open at Memorial Sloan Kettering as well as Ohio State University. And hopefully we will learn a lot from this study. Mostly the adverse effect profile with cladribine plus rituximab, it's a highly effective treatment, but again, there can be long-term immune suppression, risk of infections, the things that we worry about in patients with hairy cell leukemia.
Hopefully with vemurafenib plus obinutuzumab, we won't have those long-term problems. We did have a question earlier about what are the long-term problems that can be seen with vemurafenib. The data mostly comes from the solid tumor world, patients with vemurafenib. Even in the, not just the long term, even like in the short-term setting, shortly after use, patients are known to have increased risk of skin cancers, including squamous cell carcinoma, basal cell carcinoma, and specific kinds of skin cell diseases called keratoacanthoma. So these can increase. Vemurafenib can also cause side effects like joint pains, muscle aches and pains.
Usually it goes away after the treatment is done, after the four cycles of treatment are done, but there are a handful of patients where this can persist over time. It can also lead in the long run to some eye changes with eye dryness or increased risk of inflammation of the tissue of the eye. That can happen in the long term also. And very rarely it can cause some changes in the soft tissue of the hand where there's increased fibrous tissue that can form, especially in the hands and feet, which can eventually cause like what we call Dupuytren's contracture or plantar fasciitis, but these are very rare complications.
And we try to offset those complications with the second-generation BRAF inhibitors like tovorafenib.
Emerging Targeted Treatments: Tovorafenib and Venetoclax
This is a study where we are combining tovorafenib, which is a vemurafenib-like medication, but does not have some of the side effects that we see with vemurafenib. The study is open at Ohio State University and a few other centers. For now it's in the relapsed/refractory setting. Once we complete the relapsed/refractory part of the study, we will go to frontline, where tovorafenib plus rituximab will be compared to cladribine plus rituximab. Venetoclax we discussed. It's a BCL-2-targeting agent. This is a drug that is approved in a number of B-cell malignancies, especially CLL.
Again, it's in clinical trials with hairy cell leukemia, and we have seen preliminary efficacy with this medication. We also saw that these drugs can be combined.
What Are Researchers Still Trying to Learn?
For example, in our scientific session over the last two days, we heard about the next-generation venetoclax called sonrotoclax. This was combined in a study, this is being combined with zanubrutinib, a BTK inhibitor. One of the problems we talked about with BTK inhibitors is that they have to be given in a continuous fashion. Hopefully, when we combine it with other agents, the treatment changes from continuous treatment to more time-limited treatment. We have seen that in patients with CLL. Hopefully, that will be the case in patients with hairy cell leukemia as well.
So this is the gist of what are the treatments that we currently have and what are we looking forward to in research, ongoing research. But what are researchers still trying to learn? There are still unanswered questions for hairy cell leukemia. For example, what is the optimal treatment? We know about cladribine, but does every patient need rituximab? Or if every patient needs rituximab, do we still think concurrent is better? That means giving them together. There is another regimen. There's no delay by six months, but there's a delay by one month, like four weeks.
Is that better than concurrent? Is there a specific population of patients for whom cladribine alone is enough? We saw patients 10 years out, they are still in remission. Is there a specific population that concurrent alone is enough for them? So, we have to tease out these differences where we can use more personalized treatment for our patients. Is chemotherapy even necessary? So, we have these clinical trials, head-on clinical trials, which are comparing vemurafenib-based treatment with cladribine-based treatment. We will learn from those studies whether we can get rid of chemotherapy in hairy cell leukemia.
We will be more targeted therapy-based. And which new treatments should be used, when and for whom, and which of these new treatments will lead, which get into frontline treatment, or can some of these newer treatments be used as consolidation treatments to get to what we all are here for, for curing hairy cell leukemia? Can those be used for that? What about variant? I didn't spend a whole lot of time talking about the variant. Variant is hairy cell leukemia. It's debated a lot nowadays. The definition is changing. How should it be classified?
We don't even know that. And what are the best treatments? For now, we do CDAR for them, but is there a different treatment for them? What is their molecular profile? What is their genomic profile? We are still learning all of that. And how should other aspects of health be supported? We heard an excellent talk by Dr. Banerji about that, and that is also evolving.
The Take-Home Message
So the take-home message is not everyone needs treatment right away. Monitoring can be the right plan for some patients for some time. For classical hairy cell leukemia, cladribine or pentostatin, sometimes with Rituxan, remain important treatment options. Targeted treatments can be used in selected situations, including when infections or previous treatments affect the choice. The best option depends on your hairy cell leukemia type, blood counts, symptoms, infections, prior treatments, and especially your preference for what you would like after hearing all of these pros and cons about treatment. Clinical trials may provide access to promising approaches.
We highly recommend clinical trials when and where they are accessible to you. And when you go to see your doctor, go with information and ask questions. Ask, "What's the goal of the treatment that's being chosen for you? How will we know if it's working? What side effects should I watch for? And what are my options if hairy cell leukemia returns? Whether it returns early, will the options be different from if it returns later on?" So these are all things that we can discuss in the panel, but thank you so much for your attention.
This transcript has been edited for clarity.
Treatment Today: Expert Panel Discussion (to listen to the audio, click ▶)
Following Dr. Bhat’s presentation, she facilitated a panel discussion with Dr. Robert Kreitman, Dr. Michael Grever, and Dr. Jae Park. You can listen to her opening remarks for the panel discussion and to each speaker’s initial remarks. A full transcript of the expert panel is also available.
-
Dr. Kreitman is a senior investigator at the National Cancer Institute and head of its Clinical Immunotherapy Section. He is internationally recognized for his research and clinical expertise in hairy cell leukemia. His work focuses on targeted therapies, immunotoxins, molecular testing, minimal residual disease, and emerging treatments for classic HCL and HCL variant.
-
Dr. Grever is a hematologist and professor emeritus at The Ohio State University with more than four decades of experience in leukemia research and patient care. Internationally recognized for his expertise in hairy cell leukemia, he has helped lead influential clinical studies and international treatment guidelines. He also serves as chair of HCLF’s Scientific Advisory Committee.
-
Dr. Park is a hematologist-oncologist and Chief of the Cellular Therapy Service at Memorial Sloan Kettering Cancer Center in New York. He specializes in treating leukemia, including hairy cell leukemia. His research focuses on developing more effective, personalized treatments, including targeted therapies, immunotherapy, and chemotherapy-free approaches. He has led important clinical research in HCL, including studies of vemurafenib and obinutuzumab for newly diagnosed patients.
-
Treatment Today: Expert Panel Discussion
HCLF Patient Seminar 2026 | Speakers: Dr. Robert Kreitman, Dr. Michael Grever, and Dr. Jae Park
Dr. Robert Kreitman
So, I'm Dr. Robert Kreitman. I'm at the NIH, the National Institutes of Health in Bethesda, Maryland. I’ve been treating hairy cell since around 1995 or so. And so my perspective in treating hairy cell has obviously changed over the years. Our first goal was to try to improve cladribine alone or pentostatin alone.
So, we combined cladribine with rituximab, and we found really astounding results with 97% of patients who were what we call MRD-free. I like to use that term because it's short. MRD is minimal residual disease, traces of hairy cells. So, we follow patients not only with blood, but also with bone marrow.
Most of the patients are happy to get bone marrows on our trials. And it's hard to actually predict what percent of patients would be happy to do that. But I'm pleasantly surprised over the years how many people are.
And it is interesting that we do find minimal residual disease in the bone marrow when we don't see it in the blood, and it gives us a few years of lead time. In our trial where we randomized patients between getting cladribine alone and getting cladribine with immediate rituximab, which started back in 2009, we found that the patients who got cladribine alone could get delayed rituximab at least six months after the cladribine, and about two-thirds of those patients were able to get completely MRD-free.
Almost all those patients were able to get MRD-free in the blood. And so we found that all those patients together, 68 patients, 34 plus 34, had a very good freedom from relapse rate. At six and a half years, only one of those 68 patients relapsed versus about 28% of patients historically that get cladribine alone.
So that was, I think a major advance, not only in getting patients MRD-free but really a more important endpoint to all of you, which is to keep you from relapsing and needing more treatment. But then that's not the regimen that I would get if I had the classic form of Hairy Cell with a BRAF V600E.
I really like the vemurafenib Obinutuzumab protocol that Dr. Park pioneered at Sloan Kettering. And I think that that offers a chemo-free approach. And it's always nice to avoid chemotherapy not only for avoiding the stem cell damage that comes from purine analogs like cladribine and pentostatin, and also bendamustine, which I have tested.
But also neuropathy, which can be a problem. And neuropathy can hang on for many years and come back many years later. A lot of patients can't get those treatments because their BRAF is what we call wild type. They don't have the BRAF V600E mutation. And our laboratory at NIH has made some advances in finding out what are the mutations that drive hairy cell leukemia in patients who don't have that mutation.
And sometimes they're BRAF mutations, and those patients seem like they're behaving clinically like classic hairy cell leukemia, but they don't have the BRAF V600E mutation. And they may not respond to vemurafenib. In fact, vemurafenib may actually make those cells grow faster if they don't have the BRAF mutation.
It's important for patients to get the BRAF mutation test, which nowadays almost everyone is getting. And if you're not getting a BRAF test, you should really find out from your doctor. Maybe it was done and you just didn't find the results. So that's how I approach first-line treatment.
I think if patients do not have the BRAF mutation, then I think the Cladribine Rituximab is a very good option. But also, I think if patients want to get Cladribine alone and be followed and see how they do, and maybe get rituximab later, I think that's a reasonable option.
Our data show that the relapse rate is very low in that approach even though there might be some minimal residual disease. Of course, there are many other treatments that could be used in relapsed hairy cell, but if we focus on frontline treatment, that's how I approach frontline treatment.
And I think clinical trials being done now to improve that such as a tovorafenib rituximab protocol that will eventually be used in newly diagnosed or frontline treatment, I think is a very interesting option. We're actually hopefully going to be part of that study but first we need to test patients in relapsed disease.
Dr. Michael Grever
One of the things I'd say is the speakers today gave you the most up-to-date, comprehensive course on hairy cell leukemia that I've ever heard, so it was a very valuable use of your time today. One of the things that I would really encourage is to consider participating in a trial, if it’s right for you, if at all possible.
Back in 2008, I was approached by members of the hairy cell leukemia community, and they asked me if there was anything more to learn about hairy cell leukemia, and I said, "Absolutely." And so they asked us to convene an international conference of hairy cell leukemia experts in Chicago. And since that time, thanks to the Hairy Cell Leukemia Foundation, we've been meeting every year.
And I've been doing clinical trials all my life, it seems, but one of the things that I've really enjoyed about this group is that there's open discussion of the findings, and nobody tries to scoop the other people with what they share at the conference. So it's really a very sincere group of investigators who are working hard to treat your disease.
So one of the things, though, that is encouraging is that there's outstanding, excellent treatment for patients receiving frontline treatment, and also we've developed these salvage regimens. And one of the things that I think is going to be important is that we continue to do research to find out what has an effect on some of the long-term consequences of treatment.
Because it's important to get your leukemia into a good remission, but then the long-term consequences of treatment have to be followed because there is immunosuppression, and there's also a concern about maybe an increased incidence of second cancers. And so we need to determine if the treatments that we're using right now are the best ones.
But one of the things that's encouraging is that there are new ideas coming along. We had at least four new trials that are just opening up, discussed at the meeting earlier yesterday. And I think the opportunity to participate in clinical trials not only can provide the best care for you, but it can provide the best care for other patients with hairy cell leukemia in the future.
I started working with Dr. Bouroncle around 1977. Dr. Kreitman was there even earlier as a medical student. So, Ohio State deserves to take some credit for Dr. Kreitman. He worked with Dr. Bouroncle as well.
She was very excited about the observation that alpha interferon was able to achieve remissions in patients with hairy cell leukemia, because before that, the only therapy that she had to offer was to do a splenectomy, and that would give you some temporary improvement in your counts, but it didn't really impact on the long-term consequences of the disease.
So I had an opportunity to do a randomized trial where we looked at alpha interferon versus pentostatin because we did a lot of the original work on pentostatin at Ohio State. And we were able to accrue about three hundred and fifty patients with hairy cell leukemia within three and a half years.
And it really showed that a purine nucleoside analog had a complete remission rate in previously untreated patients of about seventy-seven percent, in contrast to alpha interferon, where the complete remission rate was only eleven percent. So participation in clinical trials is really important in trying to find ways to improve on the long-term consequences because a lot of the studies that are reported talk about consequences maybe that might occur at four or five years after treatment.
But we really need to look at the long-term consequences too. I just had a forty-one-year-old man who came in with a very aggressive presentation of hairy cell leukemia, one of the most aggressive patients I've ever seen, and we treated him with cladribine and rituximab, and he went into remission from hairy cell leukemia.
But he just contacted me about two weeks ago, and he has an invasive bladder cancer, and he's only forty-one, and he didn't have any of the other warning signs that he might have an increased risk of bladder cancer. So we have to take this seriously, and we have to continue to do research so that we offer you the best treatment with the best long-term outcome.
So this organization is remarkable because it provides a forum for people to share their data even before it's published. And sometimes in medicine, unfortunately, people won't present their data until it's published. But this organization provides a forum for that to occur. And it's working in your best interest, and it's really important that we support it.
Dr. Jae Park
Hello, guys. So my name is Jae Park. I'm a leukemia doctor at Sloan Kettering Cancer Center, so I'm the local person here. So nice to meet you all. So just to reiterate, and I just wanted to thank the panelists and others for emphasizing the excitement here about clinical trials.
So you had asked what I usually discuss with my patients who are newly diagnosed with hairy cell leukemia. First, it's good news that our patients with hairy cell leukemia overall do very well. Reducing anxiety and talking through the process and next steps are some of the things we do.
The second is talking about when to treat. I have had some patients come in or get opinions that they need to treatment right away, and sometimes it's true and sometimes it's not. For some people, based on the blood counts, treatment is less urgent, so we have some flexibility depending on your clinical condition and then the blood counts.
So there is some flexibility in choosing the timing of treatment, based on quality of life and what else is going on in your life. That is unusual for most leukemia treatments, so that is good for this type of leukemia.
For BRAF testing, I also do agree that it is important. One thing I do want to say is that it should be tested, but the test can be negative in a bone marrow biopsy or aspirate. If an aspirate could not be obtained or the sample did not contain many hairy cells, you can get a false-negative BRAF test.
So it is important to interpret the result of BRAF testing. So if you're told that you're BRAF-negative, it's important to ask how many hairy cells were there to begin with. That can be very hard to find out, so it isn't necessarily the patient's job, but you can ask questions, double-check, or get a second opinion. We've seen patients told they were BRAF-negative and later found that the sample was insufficient and that they actually had BRAF-positive classic hairy cell leukemia.
I do think that's an important point to discuss if you get those results. The last thing I'll mention is for the treatment options. What I normally do is clinical trials. As Dr. Bhat mentioned, we have an open clinical trial with two great options for our patients, cladribine-based regimen, as heard about, and a chemotherapy-free regimen of vemurafenib plus obinutuzumab.
So you can technically get both of these therapies off clinical trial, so you can access that. But I think participating in these trials is important because we learn more together in the process. We get more frequent samples to assess the immune system than we might otherwise.
So one of the key questions is that we know that patients in both groups will likely do very well in terms of a disease response. But the consequences of immunosuppression, infectious complications, second malignancies, and other outcomes will be better captured as part of our clinical trials. We’re also studying the dosing of vemurafenib.
So we have adjusted the dose based on our earlier clinical trial with vemurafenib to find a dose patients can tolerate and that is effective. Based on that experience, we've adopted a dose for this frontline study, and we'll learn from it. It is a lot easier to do that when patients are in the study together and we're capturing all data as opposed to when patients are getting different treatments here.
What we learn from those patients is still valuable, but it will be faster and more efficient this way, so I do encourage participating in clinical trials for those reasons as well.
Edited for grammar, spelling, and readability.
-
Treatment Today: Expert Panel Q&A
HCLF Patient Seminar 2026 | Speakers: Dr. Robert Kreitman, Dr. Michael Grever, Dr. Jae Park, and Dr. Kerry Rogers
How might chemotherapy-related nerve or stem cell effects show up?
Dr. Robert Kreitman
There are different neuropathies that patients can get which can be numbness and tingling in the feet, in the hands.
Some of this can be rather disabling—very painful pins and needles. And there can be other neurologic conditions that we don’t know are due to cladribine. We can sometimes see it years after, and we don't know sometimes patients have Parkinson's.
We don't know if Parkinson's is a neuropathy that's related to neurologic degeneration from cladribine because other patients get Parkinson's who aren't part of that. And that's one of the reasons I think it's good to participate in clinical trials, 'cause clinical trials, especially large ones, can tease this kind of issue out.
These drugs are associated with neurologic toxicity. I think Dr. Chabner from NIH many years ago showed that about 15% of patients get neuropathy with a single course of cladribine or pentostatin. That is something I am concerned about, along with stem cell damage, where you chronically see low white blood cell and platelet counts in patients that have had one or many courses of cladribine or pentostatin.
And I think that the other point that's a little bit more immediate of an issue is if you have a patient with very poor counts, an ANC of about .2 or .3 and they're going into treatment, and they're planning to get cladribine, whether or not they're going to add rituximab, let's say their platelet count's about 30 or 20.
If that patient is treated with a BRAF inhibitor and rituximab, they often will not see decreases in their blood counts. If they were to get cladribine and rituximab regimen, you would see a decrease in the blood counts. We’d have to be aggressive with using G-CSF (Neupogen) 24 hours after the last dose of chemotherapy to try to avoid that or try to improve the counts as soon as we can if they're in the kind of the dangerous category where you might be admitted to the hospital with fever and neutropenia, they call it.
But generally speaking, the BRAF inhibitors combined with rituximab or by themselves will avoid that. And actually, during the COVID crisis a lot of patients were getting vemurafenib alone just to improve the counts before they got the definitive treatment of cladribine and rituximab, let's say, or cladribine alone.
And nowadays, people are getting obinutuzumab and vemurafenib. One of the reasons I like the obinutuzumab vemurafenib protocol is that because you treat with vemurafenib for almost a month, for four weeks prior to starting the obinutuzumab, you don't have this platelet count decrease that happens on day two of either obinutuzumab or rituximab.
We see this because we check counts on day two. Most oncologists, hematologists will not check blood counts on day two. They'll send the patients home, and then if their platelet count started out below, let's say, sixty or seventy, their platelet counts may go down below ten.
Some patients we've seen go down to three or four, and we haven't seen serious bleeding with rituximab or obinutuzumab started on the first day, but we do check the counts. And we were able to treat on our cladribine and rituximab protocol treating patients on day one with rituximab of cladribine treatment.
And we did see low platelets on day two and it wasn't a major problem, but some of those patients did, as I say, have to get platelet transfusions. But if you were to get vemurafenib for four weeks prior to starting the obinutuzumab, you wouldn't have to have that problem, and that's why I like Dr. Park's protocol.
But I think that I echo what he said about clinical trials. I think clinical trials are very important. One of the things that we do at NIH, we invite patients to send patient samples, especially newly diagnosed patients. And we can analyze them for patients, whether or not they're interested in our clinical trials at NIH.
And I can talk more about our clinical trials later. I have a couple pamphlets outside with some written material on our clinical trials.
What are the treatment options if classic HCL or HCL variant returns, and do patients have a choice?
Dr. Jae Park
I'll start briefly with relapsed hairy cell leukemia, and then I'll let others speak. I think there is a choice, for sure. There are options for these patients, and it depends on what they got for first-line therapy, which in the majority of cases will be a cladribine-based regimen.
If the duration of your remission, meaning the time from your first treatment to recurrence, is at least a year and a half or two years, retreatment with cladribine is a reasonable option. Whether you add rituximab the second time is something to discuss.
If you did not get rituximab the first time, we often have that conversation. By achieving a deeper remission, it may reduce the chance of needing a third therapy. If you got cladribine alone, we talk about cladribine plus rituximab if that's appropriate the second time.
Of course, the other option for those patients, A vemurafenib-based regimen too. Vemurafenib plus rituximab would be another option for these classical hairy cell leukemia patients to get. So you do have a choice, and we often have discussions about what are the reasons to avoid a repeated course of a chemotherapy if their blood counts are low, or if a prior bone marrow biopsy showed clonal hematopoiesis. As we age, we do acquire additional mutations in the bone marrow that may lead to a higher risk of a second cancer.
If we already knew that was happening, we might try to avoid a chemotherapy potentially and go for vemurafenib-based regimen.
So these are very good options for both regimens in terms of getting the blood counts up, just different side effect profiles and different risk profiles that we are contemplating.
I would usually say there are choices, and it will be a good conversation to have. Cladribine alone or with rituximab or vemurafenib plus rituximab regimen.
Dr. Michael Grever
I think the patient always has a choice. You just need to take some time to explain what the choices are. But I would agree completely with what Jae said and it's whether or not somebody was able to achieve a complete remission will have some impact on whether or not they're going to have a more prolonged remission.
But also it's important if somebody has a short response and to try to evaluate why they had a short response. It’s important to look for specific abnormalities in the leukemic cells. For example, I spend a lot of time talking about TP53 abnormalities, and if somebody has either a deletion of TP53 or a mutation of TP53, then they're less likely to get a prolonged response to the typical purine nucleoside analog, and you need to consider that.
And certainly if they didn't get a good long-term response, and if they have the specific abnormality, they may not get another prolonged response if you treat them with the same regimen. I usually try and evaluate whether or not there are specific mutations in the relapse sample that will give you some clue as to which way to go.
So I spend a lot of time talking about the choices with patients. With respect to the hairy cell leukemia variant, I know that there are many people who don't like that term and there's actually multiple variants of hairy cell leukemia. But in general they don't respond as well to a purine analog alone.
And so if you have one of these patients who looks like they have the hairy cell leukemia variant, and there are ways to identify that by the immunophenotype and whether they have the BRAF mutation, as several people have said. I know Dr. Kreitman has worked out a protocol where patients are treated with a purine analog plus an anti-CD20 antibody.
You tend to get a longer response if you have somebody with one of the variants. I also presented a case just yesterday of a woman who we treated with a BTK inhibitor plus Rituxan, and she has been in a complete molecular remission with the variant hairy cell leukemia, and she's been off all therapy for over two years, and she's remained in an unmaintained remission.
I think for patients who have the variant, it's really important to participate in ongoing clinical trials so we can get a better way to approach the majority of patients. The majority of patients with hairy cell leukemia have classic hairy cell leukemia, but you need to be aware, if somebody doesn't have a durable remission, you need to look for evidence of why.
Dr. Seema Bhat
Yeah, I would talk about the choices of treatment. I think my attitude towards choices of treatment is if I have a choice of offering different choices, my patients have a choice of choosing those different options. My job there is to steer you towards why, in my opinion, one would be better than the other.
In the relapsed/refractory setting, patients have had experience with at least one kind of treatment. For example, they have had cladribine plus rituximab, so I would definitely take into account their attitude towards that treatment. What was their experience like during their prior treatment? What were their side effects like?
What was their total feeling, overall feeling about their treatment? So that will definitely determine their willingness or unwillingness to receive that treatment. If it's beyond that two-year time period that Dr. Park mentioned, I will take into account your feeling about that treatment.
Definitely, there is the choice of vemurafenib plus rituximab, but it would be important to know what was your experience like, what did you feel about the treatment, and the side effects of the second treatment, what are your attitudes towards that side effect? Because I brought up that phototoxicity issue earlier on.
I had a patient who did not want to do vemurafenib because he was all the time in the sun. So those are the things that are taken into account. And that is where we have that mutual discussion. These are the various options. What do you think about that? This is the data supporting those different options.
Dr. Robert Kreitman
I think there's a chance that obinutuzumab and vemurafenib, or even rituximab and vemurafenib, may replace chemotherapy plus rituximab as an optimal first-line treatment.
That's possible, but I think that really requires clinical testing and really randomized trials that are being done. And also there are other BRAF inhibitors that might be safer than vemurafenib, like tovorafenib that we've heard about today.
That trial will be done and those trials should be very interesting. It's hard to talk about a crystal ball because sometimes we can be surprised at clinical data. Different side effects can come up in clinical testing that you wouldn't predict that are different in one group versus the other.
So I think that again, clinical trials are important. But I think that it's important also to know you have the target for a BRAF inhibitor. And also there are these other targets. If you have hairy cell leukemia variant you may not even know it because the cells could look like classic hairy cells.
In other words, you may call that a classic hairy cell leukemia, but it may have a MAP2K1 mutation, for example. These are things that we determine in samples that we receive. And I think that there's an advantage to having those studies done, particularly if your BRAF is negative.
Could 480 mg twice daily become the standard vemurafenib dose when combined with obinutuzumab?
Dr. Jae Park
Sure. I think that's a good question, too. When we initially studied vemurafenib, building on work by Dr. Tiacci and Falini’s group in Italy, we chose the same dose that was approved for melanoma patients.
It was 960 mg twice daily, the FDA-approved dose for melanoma. And their patients went through multiple doses, and that was the dose that was thought to be most efficacious with the acceptable side effect profile. That's how it got approved for melanoma patients. So we took the same dosing scheme for hairy cell leukemia patients when we used vemurafenib by itself at 960 mg twice daily.
It worked very well, and it worked much better than what it did for melanoma patients. So then we also began to ask the question, do we even need this high a dose? And melanoma patients get vemurafenib a long time, sometimes for years, when it continues to work. In hairy cell leukemia, we were doing it initially three months and six months limited duration.
We're getting a lot of mileage. So luckily, the hairy cell leukemia cells were very sensitive to this type of medication, so we're beginning to question about the kind of dosing. When we took the same dosing for newly diagnosed patients, in hindsight, we probably should have done different arms that were studying different dosing, but we didn't and we chose the same dosing.
At that time, the reason for choosing the same dose was that cladribine with rituximab works so well, and we were studying a completely chemotherapy-free regimen with vemurafenib and obinutuzumab. That reservation is why we had to do this study.
And part of what we wanted to do is we certainly did not want to do any less than what we can already accomplish. We want to maximize the efficacy, and we wanted to choose the same dosing we studied in relapse setting and not reduce preemptively. So we... That's another rationale of choosing the same dosing with the 960 mg of vemurafenib with obinutuzumab.
It worked very well there, too, but more than half the patients had side effects. In fact, more than 80%, close to 90%, required a dose reduction from 960 mg to 480 mg. Rash and joint pain were the two most common reasons for reducing the dose.
So based on that experience, in our randomized trial now that we are doing, that's vemurafenib plus obinutuzumab versus cladribine plus rituximab in newly diagnosed patients, we have chosen 480 mg twice daily for that reason, based on our initial experience using 960 mg in newly diagnosed patients.
Most patients were unable to continue 960 mg twice daily. The full duration was four months, but even then, most patients had a dose reduction within the first month of starting treatment and ended up staying at 480 mg.
So we're studying 480 mg. When we have the results, I'm hoping that will become the standard or recommended dose we're using for our patients. For right now, that's what we're studying in the clinical trial.
Off clinical trial also, if somebody's not able to participate in this particular study and are getting the vemurafenib and obinutuzumab off clinical trial at their own kind of close to home, I often recommend 480 mg twice daily for those patients when I speak to the local doctors too.
But so far, the follow-up, obviously we need a longer term follow-up for these patients, so 480 mg twice daily with obinutuzumab, we have about two-year follow-up from our original study. Those patients have done well. With the 960 mg of vemurafenib with obinutuzumab, we have about seven to eight-year follow-up.
Those patients have done well. So we will see the long term whether there's any downside of doing it. So far, we have not seen, because all bone marrow biopsies for those patients in 480 mg, they all have achieved MRD-negative remission. So that appears to be good, but numbers are small, so it's an ongoing study, relatively small number of patients. But preliminarily, 480 mg does appear to be effective, so that's the dosing that we're studying.
What determines eligibility for an HCL clinical trial, and how can patients and families find out if they qualify?
Dr. Jae Park
I'll speak for this particular trial that we're conducting with Ohio State. For these newly diagnosed hairy cell leukemia patients, it's an excellent question. They first need to have classic hairy cell leukemia that's BRAF-positive.
The vast majority of patients with classic HCL should have it, but it is a requirement. So far it has not been a limitation. They also need to meet the criteria we use for needing therapy.
Because just because you have a hairy cell leukemia, have a relatively normal blood count, you may not need a therapy immediately. So we define that blood count as absolute neutrophil count to one, 1.0 or below, or hemoglobin 10 grams per deciliter or below, or platelets 100 or below, 100,000 or below.
So you need to have one of these white cells, red cells, or platelets below this number of criteria. You don't have to have it all, but at least one of them to meet, at least to be eligible to go on a to go on a study. There are other criteria that's a little bit relevant, like having a good kidney function, but these are very general and then very relaxed in this particular study.
The only other thing is that if you have an active infection, sometimes it may be hard. But you could be treated for that infection and go on the study a week or two later. The other thing is second cancer. So you have a concurrent second cancer other than your leukemia for which you're receiving active treatment, that often becomes ineligible for the clinical trial, unless it's like, squamous cell carcinoma or breast cancer.
Dr. Seema Bhat
So I would like to say that in general, any clinical trial for any disease will have a set of inclusion criteria and a set of exclusion criteria. Inclusion criteria are very disease-specific. For example, we have the vemurafenib study or tovorafenib study. So those are directed to classical hairy cell leukemia.
Now, when we had the ibrutinib study, that included both classical and variant hairy cell leukemia. And then you have to have criteria for treatment, like Dr. Park discussed, and you have to have only one of them. One or more you could have. And then there are certain things that are excluded, which are general things.
If you have heart disease, if you have liver numbers that are high, you have to have adequate kidney function. Then there are drug-specific exclusion criteria. For example, we had the ibrutinib study. Ibrutinib is known to cause heart problems, arrhythmias, irregular heart rate. Someone with an uncontrolled heart rate is excluded from that study.
It also causes increased risk of bleeding, so any patient who is on another agent which increases the risk of bleeding, for example warfarin, Coumadin, or some other medications are excluded. And these exclusion criteria are mostly to prevent any adverse event which can really be very harmful for the patients and also for the study.
That will halt the further drug development. There are generalized criteria, and then there are drug-specific and disease-specific criteria.
Dr. Kerry Rogers
I think that covered it really nicely for why we have those criteria, but if you're considering participating in a study or your family member is, that's a lot to think about.
And one of the things that patients and family members can do is just email or call either a research coordinator or an investigator for the study, and just say, "Hey, can I get information on this?" Or just share a little bit of information about themselves or their family member. And they can, if you want, they can talk to you about whether or not it's a good fit for you or you'd be eligible.
And the information about who to contact for the study, I believe you have that on the foundation website. There's also a website called ClinicalTrials.gov which is not user-friendly, even for physicians and researchers. But I would encourage you if anyone's considering a study, it's pretty easy to send an email, and someone on the study team can respond.
I get these as a principal investigator for studies, and I write people back, and I put them in touch with coordinators or let them know what the deal is. So you don't have to navigate all that yourself. You can reach out to someone on the study team, and they'd love to hear from you and will help you.
Dr. Versha Banerji
And to expand on what Kerry said, ClinicalTrials.gov is not user-friendly, but you're allowed to put your diagnosis in there, and then you can see what trials are open for the diagnosis. And if you click on it, that actually does have the inclusion/exclusion criteria for those studies, and it also has the sites where the study is being run.
So you can look for a study close to home that might be of interest to you and that you can qualify for. And then you have the resources from the Hairy Cell Leukemia Foundation that can also help navigate those processes. Some centers actually have clinical trial navigators as well. And so that's something you can ask your institution to help you with.
How long does it take for clinical trial results to change the standard of care?
Dr. Jae Park
It's an excellent question, and I don't know that there's a clear-cut answer. That's why we're doing the randomized clinical trial. When I mentioned eight years, I was referring to newly diagnosed patients treated with then-new regimen, vemurafenib and obinutuzumab.
So eight years in, for most cancer subtypes will be very sufficient for us to be very comfortable with the long-term follow-up. These are very good results. No one has relapsed in eight years, excellent result. Hairy cell leukemia can sometimes relapse very late after ten years and, 15 years.
So we want to be very confident about that. But at least it gives us some confidence about eight years. Is that enough? And if the number, I think someone asked about that was the number of patients in the trial. That clinical trial had 30 patients. So it's not hundreds of patients. There are now more patients treated with this regimen outside of a clinical trial as a result of those, but we don't have a large number just yet as to what that is.
But it is a good question. It’s a question of how many years and how many patients we need to be confident. Now, randomized clinical trials are helpful because then you are concurrently directly comparing against what we consider to be the current standard of care. Even there, we still need a long-term follow-up for those, and those have only been two years of follow-up so far.
These are parallel studies. The same regimen was studied by itself and now against the standard of care, so we'll learn from both. What will be enough to choose a standard of care is a really good question. It depends.
Dr. Versha Banerji
A lot of times we need to do the randomized clinical trial to often prove that the standard is either surpassed or equivalent. But it also has impacts on how we access those drugs and those medications. And so if we don't have that data, then sometimes the funding agencies, depending on how you receive the medications, may not fund the indications.
And so that's part of the challenge. By doing trials in this manner, then likely hopefully some drugs that are currently being used, quote-unquote, "off-label" can then be used for this indication. In Canada, a randomized trial may not go through the same process through the Canadian Drug Agency, but having that data might give an institution access to the treatment because now it's been compared head-to-head with the treatment.
So yes, the outcome may take a long time to see those responses, but it's more than just the efficacy that it allows. It allows for the administration and the impact of those treatments in society to move forward as well. Yeah.
Dr. Jae Park
Whether it becomes a standard or not, it presents a very good option for patients. At least we have these eight years of data to discuss with the patients that these are the options that you can actually take. So I think that is really the benefit.
Dr. Kerry Rogers
It depends on the type of cancer, what other standard options are available, and whether the drug is on the market for another type of cancer. The ibrutinib study was added to the U.S. guidelines shortly after we got an update, with probably just a couple of years of follow-up for some patients. The participants in that study, some of them had almost no otherwise effective options.
So it could be 10 years, it could be two years. It depends on a lot of factors. And in acute leukemia, it's even shorter 'cause that's a really highly fatal cancer. So in hairy cell leukemia, it does take longer mostly 'cause people are doing so well.
Living with Hairy Cell Leukemia
Living with HCL or HCLv involves more than medical treatment. Discover how nutrition, balanced eating, food safety, and everyday habits can support your health and well-being. This session offers practical guidance to help you manage common challenges, maintain your strength, and make informed choices throughout your HCL journey.
NUTRITION AND DIET FOR PATIENTS
Ernestine Trujillo, MS, RD, LD, UNM Comprehensive Cancer Center
-
Ernestine Trujillo is a Senior Clinical Nutritionist at the University of New Mexico Comprehensive Cancer Center, an HCL Center of Excellence. She has more than two decades of experience in clinical nutrition and healthcare, including over a decade supporting people affected by cancer at UNM. Her areas of expertise include oncology nutrition, medical nutrition therapy, and individualized nutritional support.
Registered dietitian Ernestine Trujillo shares practical ways for people living with HCL or HCLv to ensure adequate nutrition before, during, and after treatment. She covers small meals and snacks, hydration, food safety when your immune system is weakened, and ways to adapt your meals when side effects get in the way.
Key takeaways
Make room for a variety of foods to help meet your energy and nutrition needs.
Adapt meals to how you feel.
Pay attention to fluids, calories, and protein.
Handle food carefully when your immune system is weakened.
Check with your care team before taking supplements.
Ask for help with fatigue.
View a recording of Ms. Trujillo’s presentation below.
-
Nutrition — Hairy Cell Leukemia
HCLF Patient Seminar 2026 | Speaker: Ernestine Trujillo, MS, RDN, LD, UNM Cancer Center
Thank you for inviting me. I feel honored to share my passion with you.
Nutrition With HCL
Nutrition with hairy cell leukemia. Some of the main things I hope to address today are nutrition during treatment and nutrition in remission, since we tend to have a lengthy remission for this diagnosis.
Nutrition is very important, especially for preventing secondary types of cancer and keeping you well for as long as possible. We also want to talk about tips to manage fatigue.
Optimal Nutrition
So, optimal nutrition. I feel like our cancer centers, our providers, and nursing staff hit the nail on the head. They push that protein. We know protein's important: the beans, the hummus, the lean proteins. But we also want to make sure we don't forget about all the other pieces, the immuno-supportive nutrition.
That's our fruits and our vegetables, our micronutrients, our vitamins, and we're going to talk about that today as well. Complex carbohydrates are literally the key for energy for our bodies, so we want to make sure we're including those as well. And healthy fats, they help lubricate our joints, help our brains, and can help us get adequate calories. They're also cardioprotective for our hearts.
When's optimal nutrition important?
Before treatment, during treatment, and after treatment.
Protein
So let's get in deeper on the protein. So like I said, our centers are very good at hammering home protein, but why? Why is protein so important? It's the building block of every single cell in your body. So if we're going in there to kill cancerous cells, and we need to develop new healthy cells, you need those building blocks, and protein is one of the main ones.
It's needed for healing. Muscle mass—I put 30, 30, 30 because there is some research in building muscle that making a goal of 30 grams of protein for each meal, breakfast, lunch, and dinner, can have better outcomes for us who are trying to rebuild or add muscle mass. For women, that can be a little harder for us just because we don't have as big of appetites as our male counterparts.
Our body sizes are smaller, so we don't get as many calories. So a reasonable goal for women is about 25 grams per meal. Sources of protein include beans and hummus, meats and fish, milk, cheese, nuts, seeds, and eggs. I love to include eggs in planning with my patients just because they're so easy to prepare and so easy to digest.
It's needed for healing. Muscle mass—I put 30, 30, 30 because there is some research in building muscle that making a goal of 30 grams of protein for each meal, breakfast, lunch, and dinner, can have better outcomes for us who are trying to rebuild or add muscle mass. For women, that can be a little harder for us just because we don't have as big of appetites as our male counterparts.
Our body sizes are smaller, so we don't get as many calories. So a reasonable goal for women is about 25 grams per meal. Sources of protein include beans and hummus, meats and fish, milk, cheese, nuts, seeds, and eggs. I love to include eggs in planning with my patients just because they're so easy to prepare and so easy to digest.
Plant-Based Eating
What about plant-based eating? This is a buzzword in the media. The media tends to make plant-based eating look like it's the same thing as vegan food or veganism, meaning no animal products. However, true plant-based eating simply means that you have more plants on your plate than you have animal products.
So using animal products as the accessory to your meal—a little cheese on top, a little egg on top, a little chicken on your salad. That's still considered plant-based eating, and we're going to talk about why that's so important. Choose more whole and unprocessed foods when you can. But what if you're not feeling well?
What if you just need something instant to get some fuel in your body? That's okay, too. I want to talk about phytochemicals. The root word phyto just means plant. But I like to think of phyto as "put up your boots and fight." Plant-based compounds that help fight cancer. So I like to include this rainbow slide to show where we get all those phytochemicals.
It's from the different colors of fruits and vegetables. Has anyone here heard of "eat the rainbow"? Eat the rainbow means including all the different colors of fruits and vegetables. That ensures we get the different micronutrients. Plants show us their superpower in the color of the fruit or the vegetable.
So that's what we want to include by eating the rainbow.
Carbohydrates
Carbohydrates. Our poor friends, carbohydrates, have gotten a bad rap, right? There are really a lot of people who try to cut them out of their diet, and then they're wondering why they're feeling so tired. Carbohydrates probably got that name because we know they eventually turn into sugar in the body.
However, we can balance that out if we include carbohydrates as part of a balanced meal with a little bit of protein, fats, and even fiber. Fiber's often built right into the carbohydrate itself. So we can look at whole grains that have at least three grams of fiber per serving to be considered a good source of fiber.
Now, what's fiber good for? Fiber helps scrub out the intestines and helps get some of the junk, the waste products, to the toilet. They don't need to stay in our body. So choosing some of those whole grains will help slow down the glycemic response, how quickly your body turns that food into sugar.
Fats
We have various types of fats. Fats are our most compact form of energy, though. So if you don't have much of an appetite, adding a little bit of fat to your food can help get the calories you need to make it through your day. But there are better choices than others. We know that animal fats aren't necessarily the most healthy for our hearts and other reasons, but omega-3 fats are considered anti-inflammatory.
And let's talk about inflammation for a minute. We know inflammation is a natural response in the body, so when we eat anything, our body has to figure out, is this poisonous? Is it safe for me to eat? So it creates a little bit of inflammation. But we know prolonged and chronic inflammation, for example, when we're eating nothing but sugar and fried foods, when we're not exercising, when we're all stressed out, those are all pro-inflammatory situations, increasing our inflammation, increasing our potential for disease such as cancer, heart disease, and diabetes.
So omega-3 fats can help temper that down. So I like to try to include fatty fish. Fatty fish include salmon, tuna, trout, anchovies, and sardines. There's so many great ones to choose from. Walnuts and chia seeds are plant-based sources of those omega-3 fats.
Other healthy fats I often use when helping patients plan meals are olive oil, avocado oil, and nuts.
Why Is HCL Different?
It'd be great if we could get all the fruits and all the vegetables and all the lean proteins worked in, and all the healthy oils, right? But often at diagnosis, you start out with a suppressed immune system.
So sometimes that gives us a little bit more precautions. We need to be more careful with what you're eating. Then we throw in a treatment that may even further lower your blood counts. So with the lower blood counts, we create this perfect storm of fatigue—not having the energy or the will to want to get up and prepare a meal or have a lengthy process to create the meal.
We also make eating harder by having some side effects with our treatments, right? So nausea, vomiting, poor appetite. Who says, "Oh, great, I'm going to go thoroughly wash all my fruits and vegetables when I'm just not feeling well"? So we need to be able to roll with the punches, be able to accommodate how you're feeling in that moment and your nutritional choices.
Basic Building Blocks
So again, we're going back to the basic building blocks. We talk about protein, but really there's not one single food that is going to improve my counts. I once had a patient come into my office and say, "I eat a can of green beans every day for my counts." Great, but what about all the other fruits and vegetables?
What about eating the rainbow? She's probably missing out on some wonderful micronutrients from other foods. So we also want to make sure that we're supporting your body with adequate calories. Without adequate calories, you'll probably lose weight, and that may not be the goal for you, especially during treatment.
We want adequate micronutrients. Remember, eating the rainbow, phytochemicals, colorful fruits and vegetables. Variety is really our diet's way of providing checks and balances. This thing might be really great for us. If we had it together with something that's not as great for us, maybe they'll balance out a bit.
Increased Risk of Infection
We know that hairy cell leukemia with a suppressed immune system can put you at increased risk for infection. So what about immune-boosting nutrients? I'm not going to sit here and read through every list of the foods. I put some examples for you, and it sounds like these are recorded, so you can look at the slides later.
But we know that vitamin D is important for your immune system, zinc and vitamin C. It's important to take immune-enhancing nutrition seriously, even when your counts have improved, because we don't know how long it's going to take for your immune system to fully rebound from treatment.
Anemia: Blood-Building Nutrients
So iron, we know those red meats, just by the way they look, are higher in iron. Who here might have an old iron skillet stuck somewhere in their camping trailer? That's also a great way to transfer iron into your foods. It's just so heavy that we've gotten out of using that. But that's one of the things I often recommend for my patients who are deficient in iron.
Plant-based iron, as in leafy greens, nuts and seeds, and soy, is bound in the plant structure. So when it's found in the plant structure, it's hard for us to unlock. So how we unlock it is by eating adequate vitamin C. So that doesn't mean taking a pill or taking a powder; that means adding some vitamin C foods.
So vitamin C foods include our citrus, of course, spinach, strawberries, and someone mentioned, I have to have a New Mexico plug, Hatch green chile. But really, all peppers have that higher vitamin C content. So by pairing a big green salad with mandarin oranges and strawberries or kiwi, we're helping our body to increase the absorption of that iron.
Other anemia nutrients include folate, B12, and vitamin K. Vitamin K is involved in blood clotting. Notice how many times on these lists you see the leafy greens. So it's important to include those things, but what if your immune system can't handle it very well? What do we do? We'll talk about that later. I'm from a practice of choosing foods first.
Choose Foods First
A lot of times, at diagnosis, I have patients who walk into my office with a big bag of supplements, and people say, "My friend, my neighbor…" Every patient is a different situation. Please consult your medical team before you just take a bag of pills that your friend or a vendor at the Nutri Shop on the side of the road told you to take.
It's all very risky, in my opinion. So supplements are not well regulated, so we want to make sure that you're consulting with a professional who knows what it is that you're taking. Getting the nutrients from food is also better than from a supplement because of food synergy.
Let me give you some examples. So turmeric, we know that beautiful antioxidant that makes our bright foods yellow, such as curry. It's a powerful cancer fighter when used as a spice, right?
Our bodies increase the absorption when we have it together with a source of pepper. So the chemistry is there. Go ahead and try getting turmeric in your foods rather than trying to take a big pill or a tincture of turmeric. Supplement only if your providers tell you to, and we'll get to that too.
Supplements
Check with your provider before you take herbs, powders, vitamins, tinctures, special teas.
These all have the potential to interact with your treatment, so we want to be careful. In my brain, I try to limit the gray area, and the problem is maybe they're helpful, but what if they're harmful? I want to talk about antioxidants in that way. "Antioxidants" is another buzzword in the media, right? Healthy.
And do we know why? Antioxidants help preserve our DNA, so they help keep us looking younger. They help prevent diseases. But in a megadose, for example, "Oh, I just took this big packet of 1,000 milligrams of vitamin C," it may be too much. It may offer cancer cells DNA protection from the treatment itself.
So before you take supplements during treatment, please ask your provider. What about probiotics? Another buzzword, right? Healthy probiotics. But these are live active cultures, so if your immune system is suppressed at diagnosis and further depressed by your treatments, live active cultures may take advantage of opportunistic infection to overcome.
We want to avoid megadosing any single nutrient. So the quick and easy check that I do, if you've got, say, a multivitamin, you turn over the bottle. What are the percentages? If you've got 50% or 75% of the RDA, probably fine.
What if you've got 500% of the RDA? That's a big dose. For the general population, we'll probably just pee it off. But if you've got chemotherapy or other treatments, it may be less optimal for you. And then remember the food synergy. We cannot match food synergy in any pill or tincture.
Liquid Nutrition Supplements
What about liquid nutrition?
A lot of my patients who either don't have the energy, don't have the ability to get a balanced meal, we do use liquid nutrition. There are many different types of liquid nutrition here in the United States.
These are for patients who just need that protein support without necessarily the extra calories. Mid-range between maybe 250 to 300 calories per serving.
And then we have some really high-calorie supplements, the big guns. We reserve those for the patients with the lowest energy levels, patients who may be losing weight.
They're more complete and balanced, so if you can't get up to make the next meal, having one of these higher-calorie supplements may help you to get your needs met and be on your way to a day that you feel a little bit better. Many of these are available by prescription, so please consult with your medical team.
Hydration
When we're talking about liquids, let's talk about hydration.
So, some of these medications—we just talked about reviewing your kidney labs before you're eligible for a study, right? We give these medications, which are sometimes very hard on the kidneys to process. How do we protect our kidneys? It's with adequate fluids. Get those kidneys flushed out. A lot of my patients ask me if electrolytes are necessary.
Taking a sports drink, taking a powder. The beauty of electrolyte drinks is that they have that little bit of salt. That little flavor of salt helps stimulate you to drink more and more. But it's not necessary for everyone. If you're eating well and drinking enough fluids, probably fine without.
But if you've got a special situation like vomiting, diarrhea, or you're sweating excessively, we lose our electrolytes that way. So it could be helpful for some people. Again, consult your medical team. One thing I hear a lot is, "Oh, I can't do more water. The water tastes funny. The water's not appealing. I just can't do it."
Good thing we can meet your hydration needs in other ways. The protein shakes, soups, popsicles. If it melts and is liquid at room temperature, that's going to help you with your hydration needs. So we get creative in meeting you where you're at.
Potential Treatment Side Effects
These are the symptoms I see most often in my clinic that affect nutrition.
Nausea/Vomiting
When that's present, try to have small, frequent meals. A little meal is more achievable than a big plate of food. Try bland foods.
This is not the time for the Hatch green chile. Try dry foods, like crackers, a few bites of tortilla, a slice of sourdough bread. Sometimes if we can settle that stomach, it helps us balance out our blood sugar and lets us get to the next meal. Cool foods are probably better tolerated, so our nose is very activated sometimes when we've got nausea.
So if we activate our nose by heating up the food, we're probably less likely to eat it. For that reason, the next two things, covering the food between bites or asking friends and family to prepare meals for you, that could be important because you don't have to sit there at the stove smelling the food cooking for an hour before you try to eat it.
Drink fluids between meals because if you eat and guzzle water at the same time, it creates like a seasick effect in your belly. So we want you to separate it out, sip the fluid at the meal, and then hydrate between. Some of my patients are clock-watching. On the even hours, we're having snacks. On the odd hours, we're having drinks.
So alternate throughout the day. Mint and ginger, we know, are natural digestives. So a lot of times these are enough to help fight the nausea. Some of my patients, even just smelling the mint triggers a little bit of comfort for their nausea. Stagger your medications. A lot of patients have their anti-nausea medications, and they don't realize that they can overlap, taking one at noon and the next one at 4:00 and leapfrogging throughout the day just to keep their symptoms at bay.
Poor Appetite
You're going to see it probably every slide. Small, frequent meals are the answer. And eat what sounds good. Sometimes we say, "Oh, I want those phytochemicals. I want the rainbow."
But if it just doesn't sound good right now, go ahead and give yourself the liberty to eat what sounds good in that moment. We talked about setting a timer. Just because our body's not giving us the internal cues that, hey, it's time to eat, we need an external reminder. I also ask caregivers, step up and say, "Hey, Dad, when's the last time that you had a snack?"
It can get a little touchy if someone's got a poor appetite, so we have to find ways within the family to approach these poor-appetite patients. Leave snacks available. So if you've got, say, a shelf-stable item you can put by your favorite chair or next to your favorite section on the patio, your eyes will remind you, hey, it's time to have a snack if your tummy isn't giving you the signals.
Unintentional Weight Loss
Unintentional weight loss. Surprise, small, frequent meals. Just giving your body that opportunity for fuel. Eat enough protein and calories. So we hammered home the protein, but you need the calories to support you as well. Consider liquid nutrition supplements with higher calories, as we talked about earlier, if you've lost weight and need to regain it.
Diarrhea
What about diarrhea?
Bland diet, again, no spicy foods, but refined lower-fiber carbohydrates are easier for you to tolerate. So if I'm trying to get whole grains and all this fiber and I've got loose stools, we just talked about how that fiber helps scrub out the intestines. When you've got diarrhea, you don't need extra scrubbing.
We need something gentle and easy. So this is the time for the sourdough, the white refined flour, easy for the body to absorb temporarily until you start feeling better. Lean proteins are usually well tolerated, and remember, for every loose stool that you might have, you need an extra cup of water to make up that difference.
Cooked fruits and vegetables are easier for the body to tolerate than fresh fruits and vegetables. Soluble fiber, pectin—does anyone know what that's used for?
Yep, a thickener, jams, jelly. So that's what we want to happen in your body. Thicken the stool. We can do that with bananas, applesauce, with oatmeal.
Mouth Sores
Some of the effects are affecting your mouth. If your mouth is uncomfortable or tender, choose soft foods, choose cool foods.
Whatever you do, please don't stop eating. I have this little remedy I use: a teaspoon of salt, a teaspoon of baking soda in a mason jar of water. Shake it up, rinse and spit. Before meals and after meals, it helps with mouth health, and I feel like my patients are a lot less likely to get some of these mouth sores when they've used that baking soda and salt rinse. Magic Mouthwash may be available from your provider, just know… And that tends to have the lidocaine, which numbs the mouth a bit, but it just works for a very short amount of time, so have your meal ready if you're going to use Magic Mouthwash.
Foods to Avoid
We're all adults here. I like to tell my patients, "I'm going to give you the information, but you're driving the bus. I'm just a passenger on your bus." So you get to choose what you want to do. But there are foods with much higher risk for patients with hairy cell leukemia. Those that are undercooked, like a rare steak, runny eggs. Runny eggs, probably not the safest thing if you're in treatment or even before treatment if your counts are low.
Old and expired foods. That can of who-knows-what that's dented… in Grandma's pantry, probably not the safest choice for you. Foods that are not handled properly. So this is caregivers, making sure that you're being careful of what's being fed to our patient. Foods that may irritate your digestive system, because a lot of times it's inflamed. Spices, alcohol, and acidic foods.
Foodborne Illness
What is a foodborne illness? Foodborne illness is basically more commonly known as like a stomach bug, stomach flu. For the general population, we can get over it in a few days. For someone with hairy cell leukemia with depressed blood counts, that could end you up in the ICU.
So we want to be careful to avoid these if possible. And these are the symptoms that are often associated.
Food Safety
Let's look at food safety. You want to eat your hot foods hot, and you want to eat your cold foods cold. So again, we're at the church picnic, and you see the potato salad sitting on the buffet line for the past four hours.
Probably not safe for you if your counts are low. We want to eat cold foods cold, hot foods hot. In restaurant eating, avoid buffets. What if little Timmy just came in before you, grabs the same tongs that you did, and then you transfer that to your food? Have food that's prepared specifically for you if you're going to eat in a restaurant.
The other list of foods to avoid, raw or undercooked, we talked about. Unpasteurized, so the farm stand on the side of the road, probably not the safest place to get your dairy. I've had so many restaurants offer me fresh-squeezed juice. But when's the last time your machine was sanitized? Whose hands handled the oranges?
Were they washed before you put them in there? Who knows? So pasteurized fruit juice would be safer for you. Unwashed fresh produce. I've had some of my patients tell me they've been put on a neutropenic diet. Have you heard of that before? So a neutropenic diet is low microbial, so we said no fresh fruits, no fresh vegetables.
And it was just someone's idea until it was actually studied. When we studied pulling all those fruits and vegetables away from patients, they actually had worse outcomes. So rather, the idea is wash them, and if we still feel unsafe, then cook them. But whatever you do, don't just pull them out of your diet.
Soft cheeses, if you can see the blue veins and the green veins, the mold, probably not the safest. Hot foods, hot dogs, and deli meats tend to carry bacteria inside. They're heavily processed and then put back together. Who cleaned all that equipment?
Don't eat those foods cold. You want to eat them when they're piping hot. Raw alfalfa sprouts, any kind of green sprouts, great nutrition, but they grow low on the ground. We know what we treat the soil with, right? So it's hard to make sure that those are cleaned enough. So have those cooked if your immune system is depressed.
Washing
Washing, that's the single most important anti-infection protocol that you can have for eating. Wash your hands before you eat. Tell your family, tell your friends. If your neighbor wants to prepare you a meal, wonderful, but they need to make sure they wash their hands, and it's okay to ask that. How long is long enough?
20 seconds. If you've ever tried to count, it takes forever. So a little trick, singing yourself "Happy Birthday" twice. Okay, that's 20 seconds. Yeah, it's a long time. All right, so that just helps ensure we get all the bacteria off our hands. We want to be washing our cooking surfaces and utensils frequently so we don't cross-contaminate.
If you've got, say, a bag of spinach, how many times have we seen those greens in the news? The prewashed spinach is putting you at risk. If we've got an average immune system, fine, but if our immune system is low, wash them again. You can just have clean running water for 20 seconds, and I like to give them some agitation to work out some of the bugs, literally.
At the Market
So at the market, what do you do? Check the expiration dates. Avoid dented and damaged cans.
Because of the risk of botulism. Inspect fresh fruits and veggies. If you have a damaged fruit, that's where the bacteria tend to grow, so choose the ones in nice condition. We talked about heating up your deli meats, and premade salads.
Probably not the best for you because you've got too many opportunities for contamination, but make your own at home, and that would be a safer alternative.
In the Kitchen
In the kitchen, ensure things are fully cooked. Most of my patients, I ask them, if their immune system is down, to invest in a food thermometer.
Have you ever put a chicken in the crockpot and then you've seen near the bone there's some redness even though it's been cooking all day? How do you know what the temperature is unless you really check? So if your immune system isn't strong enough, I recommend you invest in that thermometer. Avoid cross-contamination.
Many of my patients have a vegetable cutting board and a meat cutting board, and the reason why is because we never cook the vegetables to the same internal temperature that we cook the meats to. So what that means is that if we cook it all together, our vegetables are either going to be mushy if we cook them enough, or they're going to still have bacteria from the meat. Food storage, leftovers, if you know you're not going to finish food, get it to the refrigerator within two hours, if not sooner.
Bacteria thrive at room temperature, so they can grow when food is left out on the counter. Expired foods, not for you. And I recommend, when in doubt, throw it out.
USDA
Here's a slide I pulled directly from the USDA. It talks about the internal temperatures of foods.
Fatigue
All right, let's talk about fatigue. So a calorie, by definition, is a unit of energy. So making sure that you have enough calories to meet your needs. Some of my patients have spent their whole lives trying to control calories and limit calories, but if you don't have enough, you're never going to have the energy.
I like to think of it as driving cross-country. If you try to do that without putting any fuel in your tank, you're not going to get very far, so you need fuel in your tank. You probably already said it, small, frequent meals, right?
Get those fueling opportunities inside your body. Protein, muscle protective. If you've lost weight intentionally, you've likely sacrificed some muscle. If you've lost weight unintentionally, it's likely a bigger chunk of muscle. What that does is leave you fatigued, and that's what we want to avoid.
Carbohydrates, remember, the most readily available form of energy. However, if we go with simple sugar, that doesn't give us lasting energy, so we want more complex carbohydrates, whole-grain carbohydrates, if tolerated. And we want to balance them out with protein and fats so that it keeps our blood sugar stable.
If we can keep that blood sugar stable, it's going to keep us from dipping and then craving more carbohydrates to bring us back up. Exercise and movement. At the beginning of my presentation, someone asked me, "How do we have non-caffeine sources of energy?" And it's really going to be our exercise and our movement.
I included them together. So movement, if you can't go outside, if your immune system doesn't allow you to interact with people, in your own home, you can sit to stand five times every hour.
Getting that blood flowing, getting that muscle movement is going to help you with your appetite, and it's going to help you with your energy.
Summary
In summary, if you're in the middle of treatment, roll with the punches. Allow for the treatment side effects because we know when you're feeling better, you're going to try to get back to eating well.
If it's just auntie's mac and cheese that sounds good right now, then go ahead and have it, and when you start feeling better, we're going to go and introduce those phytochemicals and colorful foods. So eat well when you can, when you feel well enough to do so. Keep food safety in mind before treatment, during treatment.
And the other thing is, once treatment's ended, we don't have a good indicator of, oh, it's time to start the alfalfa sprouts again. So always try to wash your hands and be safe with the foods you prepare. Small, frequent meals. That's going to be really a remedy for so many of these side effects of treatment.
Before, during, and after, eat a variety of colorful plants if you can fit them in. Hydrate well to protect your kidneys and also your brain function. Eat enough calories and protein to maintain your energy and strength. And if you have the opportunity, see a registered dietitian. This is what we've dedicated our careers to, helping you in your journey to tailor how to fit all these things into your home, your situation.
You don't have to do it all by yourself.
This transcript has been edited for clarity.
-
Nutrition and Wellness Q&A
HCLF Patient Seminar 2026 | Speaker: Ernestine Trujillo, MS, RDN, LD, UNM Cancer Center
Questions were condensed for clarity.
Is it better to eat organic fruits and vegetables when possible?
Ernestine Trujillo
Organic is more expensive. If you can afford it, go for it. But say you’re at a chain store and they don’t have an organic section. You would do yourself a disservice by skipping the fruit or vegetable just because it isn’t organic.
Choose organic if you can. Other fruits and vegetables are okay to have, too. Still wash your produce, including organic produce.
Do you recommend using a produce wash?
Ernestine Trujillo
The research supports washing produce for 20 seconds under clean running water. For patients with well water, I make sure their well has been tested in the past year. A produce wash isn’t necessary.
One thing I’d like to mention is vinegar. It doesn’t really make produce any safer, but it tends to reduce mold growth, so it can make your vegetables last longer.
What about sugar and desserts for people living with cancer?
Ernestine Trujillo
That’s probably the number one question I get. For some types of cancer, before you go in for a scan, they’ll say, “Let’s limit carbohydrates and simple sugars.”
But if we take away all the sugar from cells in a Petri dish, some of them are smart enough to find another source of fuel. In my patient sessions, I like to say that I’m treating a whole person. We have parties, meetings, holidays, families, and travel. I don’t want you to feel like you have to miss out on those opportunities.
We focus on balancing out the sugar and making sure it doesn’t take the place of other foods. We don’t want doughnuts and Dr. Pepper for breakfast. I saw a beautiful display of multicolored fruits today. Having fiber, protein, and fat helps temper blood sugar spikes, and those spikes are what I try to control.
How much saturated fat is okay, and how can I cut back?
Ernestine Trujillo
Saturated fat does matter. I’m concerned about its effects on heart health and inflammation. If we start reducing animal foods and putting more plant foods on our plates, we’ll naturally cut down on saturated fats.
I don’t usually count grams with a patient. We look at the sources. Instead of ordering a tomahawk steak, you might have a steak salad so you have greens to balance it out. Cut down on things like butter, ranch dressing, and heavy cheeses, and opt for more plant sources.
Have some lentil soup for dinner or try a Meatless Monday. If we start cutting down on animal foods, we’ll also cut down on animal fats.
How often should private well water be tested, and what do they test for?
Ernestine Trujillo
This comes up from time to time in rural New Mexico, where some patients aren’t on a city water system. The recommendation is to have your well water tested annually.
I can’t remember the name of the specific bacterium I was thinking of. The well water testing service will know what to test for.
What should people living with HCL know about drinking alcohol?
Ernestine Trujillo
Any amount of alcohol increases your risk of some types of cancer, such as breast cancer. If your hairy cell leukemia is in remission and you’re living a long life, you still have a risk of other types of cancer.
I’m on the bus with you. It’s your choice. In the moderation example I gave, a drink was 5 ounces of wine, 1 to 1½ ounces of spirits, or one 12-ounce beer. I described moderation as up to one drink per day for women and up to two per day for men. You can’t save those drinks up and have them all on the weekend.
Alcohol is also an irritant to the digestive tract. If you can avoid it, I’d consider that.
Hairy Cell Leukemia Research
Every person's experience with HCL or HCLv can help advance our understanding of this rare disease. Learn how the HCL Patient Data Registry brings together information from people living with HCL and HCLv to support research, explore treatment outcomes, and improve future care. Discover how the registry works, how your information is protected, and how you can contribute to research that benefits the entire HCL community.
Overview of the HCL Patient Data Registry
Speaker: Mirela Anghelina, MD, MPH, The Ohio State University
Dr. Anghelina explains what the HCL Patient Data Registry collects, how researchers use that information, and what to expect if you’re interested in joining. The audience Q&A covers how participation works in the United States and internationally.
Key takeaways
The registry helps researchers learn from people’s experiences with HCL and HCLv. Projects explore treatment outcomes, quality of life, and how experiences differ across groups.
Participation is voluntary.
Researchers request only the data they need for an approved project. They submit a proposal and specify the information needed to answer their research question.
View a recording of Dr. Anghelina’s presentation below.
-
Hairy Cell Leukemia Patient Data Registry
Mirela Anghelina, The Ohio State University
I’m Mirela. I am a senior data analyst at Ohio State University. And I'm very grateful to the Hairy Cell Leukemia Foundation for this invitation. It's a pleasure to meet all of you and talk with you about this project we have at Ohio State University. It's a Hairy Cell Leukemia patient data registry. Dr. Grever here in the audience is the principal investigator at Ohio State that runs this project. The registry is hosted at Ohio State University.
Hairy Cell Leukemia Patient Data Registry
It is developed through the vision and support of patients and families affected by Hairy Cell Leukemia. It's a collaboration between the Hairy Cell Leukemia Foundation and Ohio State University Division of Hematology and the Department of Biomedical Informatics. The main goal is to build a platform that brings together patients, researchers, and healthcare providers to drive progress in Hairy Cell Leukemia care. So this registry is approved and monitored by the Ohio State University Institutional Review Board (IRB).
Institutional Review Board (IRB)
How many of you know what an IRB is? An IRB is a group of people who review research studies to make sure they are safe, ethical, and respect the rights of participants. Any academic institution that runs a research study has an institutional review board or an ethics board. It's called institutional review board in the U.S., but international academic centers have similar institutional committees that review the research at their institution. Why does it matter? If a study involves people, the IRB checks to make sure people are not harmed, they understand what they are agreeing to, their privacy is protected, and the study is fair and necessary.
Who is on these IRB committees? It usually contains scientists, doctors or healthcare professionals, but also people from the community: patient advocates, former research participants, teachers, even clergy members, priests and rabbis, and lawyers and ethicists, of course. So how can you register for this registry?
Registry Participation
So there are two ways. If you are seen at one of the Centers of Excellence that participate in the study, your provider is going to contact you to tell you about this registry and invite you to participate if you want to. You can decline if you don't feel comfortable, but you can get information about this registry from your provider. Also you can enroll in the registry via the Hairy Cell Leukemia Foundation website if you live in the U.S. We cannot enroll at this time patients outside the U.S. through that form. On the Hairy Cell Leukemia Foundation website, you can find a list of Centers of Excellence. And I think we have at least 24, 25 Centers of Excellence. So there are Centers of Excellence all over the United States. We have Centers of Excellence in Australia, Canada, Europe, and Israel. Not all of them are part of the registry yet, but they are invited to be part of the registry. Here are the sites that are currently part of the registry.
Current Registry Participation
There are eight active sites that are already enrolling patients and enter their data in the registry. They are Ohio State University, University of Rochester, University of Miami, Mayo Clinic in Minnesota, and Mount Sinai Medical Center in Florida. We have two centers from Canada. CancerCare Manitoba and BC Cancer from British Columbia, Canada, and Peter MacCallum Cancer Centre from Victoria, Australia. We have three new sites that completed their paperwork. These three institutions are Royal Marsden Hospital from the UK, Academia Nacional de Medicina from Argentina, and Scripps Health from California. The site in Argentina is our first non-English-speaking site from South America.
We are going to provide the training for the teams of these three centers in the coming months. And we hope at the end of January probably they will start adding the patients. We have another three centers where we have started the paperwork. There is Northwell Health from New York, University of Pennsylvania, and University of Padua from Italy.
Enrollment through HCL Foundation Website
As I said, if you are not seen at a Center of Excellence that is already part of the registry, you have the possibility to participate via the Hairy Cell Leukemia Foundation website. On the patient support page, you can find more information about the Hairy Cell Leukemia Patient Data Registry. And at the end of that you will find a form where you can submit your name, email address, and phone number to show your interest in participating in the registry. If you fill out this form, it doesn't mean you are going to be enrolled in the registry right away. This information goes to the Ohio State University clinical research coordinators, and they are going to contact you to give you more information about the registry.
And if you feel comfortable, they will go with you through the consent process to be part of the registry. You will sign a combined informed consent and HIPAA form and provide an authorization for the release of medical information. With this form, we are going to contact your provider and request your medical records and extract the information we need and upload it in the registry. For those participants who are already in the registry and provided this authorization by the time of consent, we might need to contact you again because some institutions require the authorization to be signed within the past year. Every year we update your medical records, so we contact your provider to give us your updated information. And some institutions do not take the old authorization form, so you might be contacted by the Ohio State University research team.
OSU Team Contact Information
So if you don't hear from us after you fill out the form from the Hairy Cell Leukemia Foundation website, here is our phone number and email. You can find this information on the Hairy Cell Leukemia Foundation website. When our team calls you, they are not going to say, "We are with the Hairy Cell Leukemia Foundation." We are not allowed to use the disease name. They are going to say, "We are researchers from Ohio State University, and we want to talk with you about the study we run here at Ohio State University."
HCL-PDR Patient Enrollment
Here is the total number of consented patients so far in the registry. So we have almost 1,200 patients who have consented. However, we have a little bit of backlog for uploading the medical records in the registry. We have 952 medical records already in the registry. I put here all the participating sites. The teams at these sites are working hard to upload the medical records in the registry.
Participants via HCL Foundation Website
As I said, Hairy Cell Leukemia Foundation provides the opportunity for you to enroll through their website. It's a great tool. We can reach many patients all over the United States. As you see we have patients from almost every state in the United States. I have here a table with the demographic distribution of all the patients who have their data already in the registry. So as I said we have 952 patients.
Registry Data Demographics
The median age at diagnosis is 54, with a range between 19 and 96 years old. We have a quarter of patients younger than 45 at the time of diagnosis. Almost… more than half of them are between 45 and 65, and 20% of them are over 65. Of course, this is a predominantly male disease, but 25% of the patients are female who are affected by this disease. And we have the same distribution in our registry, so we have a good contribution from our ladies.
The majority are White or Caucasian, but we have 26 patients who are not White. And also, the majority are non-Hispanic, but we have 21 patients who are Hispanic or Latino. The majority of patients have classic hairy cell leukemia, but also we enroll patients who are diagnosed with HCL variant. I put here some studies we published using the patient data registry.
Clinical Studies Using the Patient Data Registry
So we have the first paper… in the first paper, we described how we created this registry. In this paper, we shared our analysis about quality of life of patients living with this disease. We ran another study in parallel with the registry to assess the quality of life of patients with this disease. And we published this paper. So the patients who are enrolled in quality of life study are also in the Hairy Cell Leukemia Patient Data Registry. So we connect their reported quality of life with the clinical data from the registry. We also looked at the impact of sex on outcomes in patients with hairy cell leukemia. We have a study looking at outcomes in patients with hairy cell leukemia who contracted COVID-19.
Projects in Progress
Here I have a list with all the projects that are in progress. We are very excited that this year multiple teams requested data from the registry. The first three projects are run by Dr. Leslie Andritsos from the University of New Mexico. They already wrote three abstracts, and they were submitted for ASH that will take place in December this year. So they are going to look at characteristics and outcomes of untreated patients with hairy cell leukemia. They will evaluate diagnosis-to-treatment intervals and clinical outcomes in patients with hairy cell leukemia. They are looking for splenic B-cell lymphoma with prominent nucleoli.
This is a new name that the WHO gave to hairy cell leukemia variant. From Ohio State University, Dr. Kerry Rogers, will look at second malignancies in patients with the hairy cell leukemia. Dr. Seema Bhat, also from Ohio State University, is going to look at factors predicting worse outcomes in patients with the hairy cell leukemia. Dr. Seema Bhat also wants to collaborate with a group from Italy to validate a prognostic score that was developed by that group in Italy. Another group from Scripps, led by Dr. Alan Saven, is going to look at the clinical course of this disease in young patients.
Dr. Tamar Tadmor from Israel is going to look at outcomes in older and younger patients. And the last two studies are going to look at quality of life of patients living with hairy cell leukemia. The first one is a collaboration with Dr. Gregory Abel from Harvard and Dr. Leslie Andritsos from New Mexico. And the last one we are going to analyze a special questionnaire that we created at Ohio State University, and it's unique for patients with hairy cell leukemia.
Thanks to Our Teams
First of all, I want to thank all the patients who trust us and share their information with us and help us to better understand the disease and do research to find new ways to treat this disease. I want to thank the Hairy Cell Leukemia Foundation for continuous support on all the hairy cell leukemia projects we run. To all Hairy Cell Leukemia Foundation collaborators from all Centers of Excellence, and to my colleagues from Ohio State University, thank you so much for that.
This transcript has been edited for clarity.
-
Hairy Cell Leukemia Patient Data Registry — Q&A
Mirela Anghelina, The Ohio State University
Questions were condensed for clarity.
How can people living outside the United States participate in the Patient Data Registry?
Mirela Anghelina
There are a few Centers of Excellence that have joined the registry. We have two centers in Canada: CancerCare Manitoba and BC Cancer in British Columbia. If you are treated at these centers, you can join the registry.
I know Dr. Banerji from CancerCare Manitoba is planning to create a website where you can join the registry and complete the consent process through CancerCare Manitoba. But this is a work in progress.
We also have the Royal Marsden Hospital in the United Kingdom. If you are in the UK and are seen at this center, you can join.
Moderator
To clarify, the way the Royal Marsden set up the agreement, they will be able to register anyone in the UK, including individuals who are not treated at the Royal Marsden. That will be a great benefit for patients across the UK.
We also have a brand-new agreement in Argentina, which we're really excited about. Pretty soon, Dr. Morande will be able to start helping people get set up there.
And we have our Australian center, too.
In the United States, whether or not you're treated at one of the participating Centers of Excellence, you can complete a form on the Hairy Cell Leukemia Foundation website. That information goes to Ohio State University, and the research team follows up with you.
If someone has already joined the registry, do they need to enroll again?
Mirela Anghelina
No. You don't need to enroll again. Once you sign the consent form, you are part of the registry.
However, if you enrolled through the Hairy Cell Leukemia Foundation website, we also need a signed authorization to release your medical information. You sign this authorization at the time of consent.
We update the registry every year using the authorization we have on file. However, some institutions require us to provide a new authorization each year.
If that's the case, our team might contact you to sign a new authorization form. You do not need to reapply to the registry.
How is the information collected through the registry used for research?
Audience Member
I'm envisioning that data from the registry is loaded into a spreadsheet, and somebody looks for patterns or consistencies, maybe using Venn diagrams. Am I oversimplifying it?
Mirela Anghelina
We use a platform called REDCap.
Moderator
It's not a spreadsheet where people simply get to look at all the information.
Researchers develop questions. They're trying to understand some of the unanswered questions about hairy cell leukemia, such as secondary malignancies or the impact of the disease among younger versus older patients.
They form a hypothesis or research question and submit a proposal. That proposal gets reviewed and approved, and only then do they get access to the data needed to try to answer that question.
Dr. Kerry Rogers
When we submitted our proposal, we had to specify what data elements we wanted.
We wanted information such as age, sex, treatments, and the incidence of other cancers.
There are a lot of great research questions, but sometimes the information needed isn't in the registry or isn't something that has been collected.
That's why it's really important, as part of the review process, that we specify what data we want. Then everyone makes sure it's actually data that exists or that we'll be able to obtain.
Once that's approved, we receive the data for our project.
There's also a statistician who helps us work with those data elements. We don't receive all the information in the registry, just the data we've requested for our project.
A statistician is also involved earlier in the process, helping us plan the hypothesis and determine what kind of analysis we're going to do.
Sometimes an analysis is feasible, and sometimes it's not. Sometimes you do a slightly different analysis once you see the data.
So you specify what information you want, and that's what you receive.
Why can't international patients who are not treated at a participating Center of Excellence submit their medical records directly to the registry?
Mirela Anghelina
It's not only about the consent process. You can consent and agree to participate, but we also have to explain to the Institutional Review Board how we're going to obtain your medical information.
You cannot give us your medical records directly. We have to go to the institution and request those medical records.
So we need to have an agreement with the institution or be approved to do that in the country where the patient is treated.
We were able to establish this process in the United States. That's why people in the U.S. can participate through the Hairy Cell Leukemia Foundation website.
However, Ohio State University is responsible for the medical records we collect and the data we maintain.
We need to have someone who takes responsibility for those medical records.
That's why we want to find a center in each country that can take responsibility for obtaining the medical records, keeping them safe, extracting the necessary information, and entering it into the registry.
Moderator
Every country has its own rules regarding how patient data can be shared and protected.
That's why it's been difficult to establish some registry sites in Europe, because of the level of protection that European countries, in particular, have over patient data.
It's not that patient data isn't protected in the United States. There are simply different administrative requirements and additional steps to work through in Europe.
Because of those differences, it takes time to navigate each country's administrative rules and regulations so that patients can share their data.
That's why it took so long to establish participation in Canada and the United Kingdom. But we're making progress.
This transcript has been edited for clarity.
Support the HCL Community
Donations help the Hairy Cell Leukemia Foundation (HCLF) provide patient education, community programs, reliable resources, and support for research. Every contribution helps strengthen the HCL and HCLv community and advance progress for all patients and families.